{"gene":"LRP1","run_date":"2026-06-13T19:06:35","timeline":{"discoveries":[{"year":2000,"finding":"CD91 (LRP1) was identified as a direct cell-surface receptor for heat shock protein gp96 on antigen-presenting cells. CD91 binds gp96 directly (not through another intermediate ligand), and the known CD91 ligand alpha-2-macroglobulin competitively inhibits gp96-chaperoned peptide re-presentation by macrophages. Anti-CD91 antibodies also block re-presentation, establishing CD91 as the receptor mediating gp96-peptide uptake and MHC class I cross-presentation.","method":"Direct binding assay, competitive inhibition with alpha-2-macroglobulin, antibody blockade of re-presentation in macrophages","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding evidence, competitive inhibition with known ligand, antibody blockade, replicated across multiple subsequent studies","pmids":["11248808"],"is_preprint":false},{"year":2001,"finding":"CD91 (LRP1) serves as a common receptor for multiple heat shock proteins — gp96, hsp90, hsp70, and calreticulin — on macrophages and dendritic cells. All of these HSPs use CD91 to mediate uptake and MHC class I re-presentation of chaperoned peptides. Post-uptake processing requires proteasomes and TAP transporters, utilizing the classical endogenous antigen presentation pathway.","method":"Uptake assays with multiple HSPs in macrophages and dendritic cells; MHC class I re-presentation assays; inhibitor studies (proteasome inhibitors, TAP-deficient cells)","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple HSP ligands tested, pathway dissection with proteasome/TAP inhibitors, independently replicates CD91-gp96 finding and extends it","pmids":["11290339"],"is_preprint":false},{"year":2001,"finding":"Alpha-2-macroglobulin (alpha-2M) binds peptides in vitro and, as a CD91 (LRP1) ligand, can chaperone peptides for re-presentation by CD91+ APCs on MHC class I molecules, priming peptide-specific CD8+ T cell responses. This demonstrates alpha-2M functions similarly to gp96 as a T cell adjuvant through CD91.","method":"In vitro peptide binding assay; immunization of mice with alpha-2M-peptide complexes; re-presentation assays in CD91+ APCs","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro binding plus in vivo immunization, single lab","pmids":["11290775"],"is_preprint":false},{"year":2004,"finding":"CD91 (LRP1) is essential for re-presentation of gp96-chaperoned peptides by antigen-presenting cells. siRNA-mediated knockdown of CD91 in APCs caused a corresponding and dramatic decline in re-presenting ability; recovery of CD91 expression restored re-presentation ability. Anti-CD91 antisera abrogated protective tumor immunity elicited by tumor-derived gp96-peptide complexes in vivo.","method":"siRNA knockdown of CD91; in vitro re-presentation assays; in vivo tumor immunity assays with anti-CD91 antisera","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — siRNA loss-of-function with recovery, in vitro and in vivo validation, multiple orthogonal readouts","pmids":["15073331"],"is_preprint":false},{"year":2008,"finding":"LRP1 associates with and is functionally required for the endocytosis of neuronal prion protein (PrPC). LRP1 inhibition by siRNA reduces surface PrPC and causes its accumulation in biosynthetic compartments, indicating LRP1 expedites PrPC trafficking to the neuronal surface. PrPC and LRP1 co-immunoprecipitate from the endoplasmic reticulum, and the N-terminal domain of PrPC binds purified human LRP1 with nanomolar affinity even in the presence of the LRP1 chaperone RAP.","method":"siRNA knockdown, co-immunoprecipitation, in vitro binding assay (nanomolar affinity measurement), surface PrPC quantification","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro binding with affinity measurement, co-IP from ER, siRNA functional validation, multiple orthogonal methods in single study","pmids":["18285446"],"is_preprint":false},{"year":2010,"finding":"LRP1 is shed from macrophages by ADAM17 in response to LPS and IFN-γ, generating soluble LRP1 (sLRP1). Both sLRP1 (from human plasma) and full-length LRP1 (from mouse liver) activate cell signaling (p38 MAPK, JNK, IKK-NF-κB) when added to macrophage cultures and induce expression of TNF-α, MCP-1/CCL2, and IL-10. Ligand-binding cluster-directed proteins fail to inhibit sLRP1 signaling, but an antibody targeting the sLRP1 N-terminus is effective.","method":"ADAM17 inhibition studies; purified sLRP1 and full-length LRP1 added to RAW 264.7 cells and BMMs; western blot for signaling kinases; cytokine measurement; blocking antibody experiments; in vivo LPS model","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — purified protein added to cells, in vivo confirmation, single lab with multiple orthogonal methods","pmids":["20610799"],"is_preprint":false},{"year":2010,"finding":"CD91 (LRP1) directly binds C1q. Surface plasmon resonance and ELISA demonstrate a direct, saturable, time-dependent interaction between purified C1q and purified CD91 that is inhibited by known ligands of both proteins. CD91 expression on monocytes correlates with C1q binding, and the CD91 chaperone RAP inhibits this binding.","method":"ELISA, surface plasmon resonance (SPR), flow cytometry of monocytes, RAP inhibition assay","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — SPR and ELISA with purified proteins, specificity controls (competitive inhibition), single lab","pmids":["20716178"],"is_preprint":false},{"year":2010,"finding":"LRP1 regulates Notch3 signaling through thrombospondin-2 (TSP2). TSP2 potentiation of Notch3 is blocked by RAP (LRP inhibitor) and requires LRP1 expression in the signal-sending cell. TSP2 stimulates Notch3 endocytosis into wild-type but not LRP1-deficient fibroblasts. Recombinant Notch3 and Jagged1 interact with the LRP1 85-kDa B-chain (a subunit lacking known ligand-binding function), suggesting LRP1 and TSP2 stimulate Notch activity by driving trans-endocytosis of the Notch ectodomain.","method":"RAP inhibition, LRP1-deficient fibroblast comparisons, Notch3 endocytosis assay, recombinant protein interaction assay with LRP1 B-chain","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — LRP1-deficient cells compared to WT, RAP inhibition, protein interaction assay, single lab","pmids":["20472562"],"is_preprint":false},{"year":2011,"finding":"LRP1 directly binds leptin and the leptin receptor complex and is required for leptin receptor phosphorylation and Stat3 activation. Conditional deletion of Lrp1 in the brain resulted in an obese phenotype (increased food intake, decreased energy consumption, decreased leptin signaling). Hypothalamus-specific deletion via Cre lentivirus was sufficient to trigger accelerated weight gain.","method":"Conditional brain-specific and hypothalamus-specific Lrp1 knockout mice; direct binding assay (LRP1 binds leptin and leptin receptor complex); leptin receptor phosphorylation and Stat3 activation assays","journal":"PLoS biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with specific phenotypic readout, direct binding demonstration, regional specificity confirmed by Cre lentivirus injection, multiple orthogonal approaches","pmids":["21264353"],"is_preprint":false},{"year":2011,"finding":"LRP1 regulates the cell-surface abundance of urokinase receptor (uPAR) by facilitating its endocytosis, thereby controlling uPAR-initiated cell signaling including ERK, PI3K, and Rac1 pathways. In some cell types LRP1 directly activates cell-signaling upon ligand binding, and it also indirectly regulates signaling by modulating the plasma membrane proteome (e.g., uPAR levels).","method":"Review synthesizing LRP1 endocytosis and signaling studies; cell-based uPAR endocytosis and signaling assays described","journal":"Current pharmaceutical design","confidence":"Low","confidence_rationale":"Tier 3 / Weak — review paper summarizing prior experimental work without new primary data presented","pmids":["21711236"],"is_preprint":false},{"year":2012,"finding":"LRP1 is the receptor mediating H. pylori VacA toxin-induced autophagy in gastric epithelial cells. VacA binds LRP1 and its internalization through LRP1 regulates LC3-II generation (autophagosome formation) and subsequent apoptosis (PARP cleavage). Knockdown of LRP1 inhibited both VacA-induced autophagy and apoptosis. Other VacA receptors (RPTPα, RPTPβ, fibronectin) did not mediate autophagy.","method":"LRP1 knockdown (siRNA), LC3-II western blot, PARP cleavage assay, comparison with other VacA receptor knockdowns","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — specific receptor identification by knockdown with multiple functional readouts, negative controls (other receptors), single lab","pmids":["22822085"],"is_preprint":false},{"year":2011,"finding":"CD91 (LRP1) functions as a signaling receptor for HSPs (gp96, hsp70, calreticulin) on APCs, triggering phosphorylation of CD91 and activation of NF-κB signaling cascades leading to APC maturation, cytokine secretion, and priming of T-helper cell subsets. Each HSP-CD91 interaction stimulates a unique cytokine profile dictating specific Th cell subset priming.","method":"CD91 phosphorylation assays, NF-κB activation assays, cytokine profiling, Th cell priming experiments, CD91-dependent signaling in APCs","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — phosphorylation and NF-κB activation assays, CD91-dependent Th cell priming, multiple HSPs tested with distinct cytokine profiles","pmids":["22045000"],"is_preprint":false},{"year":2013,"finding":"LRP1 deletion in Schwann cells causes abnormalities in axon myelination and ensheathment of axons in Remak bundles, resulting in mechanical allodynia even without nerve injury. After crush injury, sciatic nerves in scLRP1−/− mice showed accelerated degeneration, Schwann cell death, and failure to remyelinate. LRP1 is identified as an essential mediator of Schwann cell-axon interactions and the Schwann cell response to PNS injury.","method":"Conditional Schwann cell-specific LRP1 knockout (scLRP1−/−), behavioral pain assays, nerve crush model, histological analysis of myelination and Remak bundles, spinal cord microglial activation assays","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type specific conditional KO, multiple phenotypic readouts (anatomy, behavior, central sensitization), specific injury models","pmids":["23536074"],"is_preprint":false},{"year":2013,"finding":"Myeloid cell LRP1 regulates macrophage migration and chemokine expression via NF-κB. LRP1 deletion in myeloid cells increased monocyte recruitment to tumors, elevated CCL3/MIP-1α expression in macrophages, and increased tumor angiogenesis. LRP1-deficient macrophages migrated faster than LRP1-expressing cells, an effect reversed by CCL3-neutralizing antibody, CCR5-neutralizing antibody, or NF-κB inhibition.","method":"Myeloid-specific LRP1 knockout mice, orthotopic tumor model, chemokine expression analysis, in vitro migration assay, neutralizing antibodies, NF-κB inhibitor","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — myeloid-specific KO with in vivo tumor model, mechanistic rescue experiments, multiple orthogonal approaches","pmids":["23633492"],"is_preprint":false},{"year":2007,"finding":"LRP1 is required for the constitutive endocytosis and lysosomal degradation of cell-surface transglutaminase. Transglutaminase interacts with LRP1 in vitro and on the cell surface (co-immunoprecipitation). LRP1 deficiency or blockade of endo-lysosomal function upregulates transglutaminase surface expression, leading to increased cell adhesion and matrix crosslinking. Fibronectin and PDGF promote transglutaminase endocytosis via LRP1.","method":"In vitro binding assay, co-immunoprecipitation, LRP1 deficiency model, surface expression assays, adhesion assays, ligand-stimulated endocytosis","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP, in vitro binding, LRP1-deficient cell comparisons, multiple functional readouts in single study","pmids":["17711877"],"is_preprint":false},{"year":2009,"finding":"LRP1 regulates reverse cholesterol transport by controlling cPLA2 phosphorylation and ABCA1 expression. Absence of LRP1 increases PDGFRβ signaling, activating MAPK which phosphorylates cPLA2, releasing arachidonic acid that suppresses LXR/RXR-mediated ABCA1 transcription, reducing cholesterol efflux. LRP1 thus functions as a physiological integrator of cellular lipid homeostasis.","method":"LRP1-deficient cells, PDGFRβ signaling assays, cPLA2 phosphorylation assays, arachidonic acid measurement, LXR/RXR promoter assays, ABCA1 expression analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — LRP1-deficient cell system, sequential pathway validation, single lab with multiple biochemical readouts","pmids":["19718435"],"is_preprint":false},{"year":2009,"finding":"LRP1 controls adipogenesis and lipid homeostasis in adipocytes. LRP1 silencing in preadipocytes inhibits expression of PPARγ, HSL, and aP2 adipocyte differentiation markers and results in lipid-depleted cells. In fully differentiated adipocytes, LRP1 silencing reduces cellular lipid levels and is associated with increased basal lipolysis.","method":"siRNA knockdown of LRP1 in 3T3F442A preadipocytes and differentiated adipocytes, adipocyte differentiation marker expression, lipid staining, lipolysis assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with specific differentiation and lipid accumulation readouts, single lab","pmids":["19823686"],"is_preprint":false},{"year":2014,"finding":"LRP1 modulates sphingosine-1-phosphate (S1P) signaling and is essential for vascular development. Loss of LRP1 leads to lethal vascular defects with failure of mural cell investment of vessels. LRP1 integrates S1P and PDGF-BB signaling pathways via its intracellular domain; loss of LRP1 prevents S1P-dependent inhibition of RAC1 and removes constraint on PDGF-BB-induced cell migration.","method":"Genetically engineered mouse models, S1P signaling assays, RAC1 activity measurement, PDGF-BB migration assays, intracellular domain analysis","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo KO with lethal vascular phenotype, mechanistic dissection of S1P/PDGF pathway integration via LRP1 intracellular domain","pmids":["25377550"],"is_preprint":false},{"year":2015,"finding":"LRP1 (along with LDL receptor) mediates mannose 6-phosphate-independent lysosomal targeting of cathepsins D and B. LRP1-deficient fibroblasts fail to internalize non-phosphorylated cathepsins B and D, and LRP1 inhibitor increases secretion of cathepsin D from M6P-deficient cells. LRP1 thus functions in a secretion-recapture targeting mechanism for lysosomal enzymes.","method":"SILAC-based comparative mass spectrometry of lysosomal proteome, fibroblasts deficient for LRP1 or LDLR, LRP1 inhibitor treatment, cathepsin secretion assays","journal":"Traffic (Copenhagen, Denmark)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor-deficient cell lines, proteomics, functional secretion assays, single lab","pmids":["25786328"],"is_preprint":false},{"year":2015,"finding":"LRP1 interacts with PARP-1 in human retinal microvascular endothelial cells, and this interaction decreases under hypoxia. LRP1 knockdown results in increased PARP-1 activity and subsequent phosphorylation of retinoblastoma protein and CDK2, promoting cell cycle progression. Endothelial LRP1 deletion increases retinal neovascularization in oxygen-induced retinopathy.","method":"Co-immunoprecipitation (LRP1-PARP-1 interaction), LRP1 endothelial knockout mice, oxygen-induced retinopathy model, Ki67 staining, PARP-1 activity assay, Rb and CDK2 phosphorylation assays","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP identifying novel LRP1-PARP-1 interaction, endothelial KO mouse with in vivo angiogenesis phenotype, downstream signaling cascade validated","pmids":["26634655"],"is_preprint":false},{"year":2016,"finding":"LRP1 microglia expression is protective during CNS autoimmunity (EAE). LRP1 functions as an inhibitor of NF-κB activation in myeloid cells via a MyD88-dependent pathway. Deletion of LRP1 in microglia (but not peripheral macrophages) increases EAE severity and causes microglia to adopt a pro-inflammatory phenotype with amoeboid morphology and increased TNF-α production.","method":"Microglia-specific and peripheral macrophage-specific LRP1 knockout mice, EAE model, NF-κB activation assays, cytokine measurement (TNF-α), morphological analysis","journal":"Acta neuropathologica communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — cell-type specific conditional KO (microglia vs macrophage), MyD88-dependent NF-κB pathway identification, specific in vivo disease model","pmids":["27400748"],"is_preprint":false},{"year":2017,"finding":"The intracellular domain of LRP1 interacts with the nuclear receptor PPARγ and acts as its transcriptional co-activator in endothelial cells. Endothelial-specific Lrp1 deletion in mice improves glucose sensitivity and lipid profiles with increased oxygen consumption under high-fat diet conditions.","method":"Endothelial-specific LRP1 knockout mice, co-immunoprecipitation (LRP1 ICD with PPARγ), transcriptional co-activation assays, metabolic phenotyping","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP demonstrating LRP1 ICD-PPARγ interaction, endothelial-specific KO with metabolic phenotype, single lab with orthogonal methods","pmids":["28393867"],"is_preprint":false},{"year":2018,"finding":"TLR activation leads to phosphorylation of LRP1 at Y4507 in macrophages, which recruits the GTPase Rab8a and its PI3Kγ effector complex (p110γ/p101) to macropinosomal membranes. CRISPR KO of LRP1 abolishes TLR-induced Rab8a activation and alters Akt/mTOR signaling, producing a pro-inflammatory cytokine bias. This TLR-LRP1-Rab8a/PI3Kγ axis reprograms macrophages to suppress inflammation.","method":"CRISPR knockout of LRP1, LRP1 phosphorylation at Y4507 assay, Rab8a activation assay, Co-IP/recruitment assays, cytokine profiling, confocal microscopy","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO, specific phosphorylation site identified, Rab8a recruitment assay, comparison with Rab8a-KO and PI3Kγ-null phenotypes, multiple methods","pmids":["30208326"],"is_preprint":false},{"year":2018,"finding":"p53 regulates LRP1 expression as a direct target gene. LRP1 transcript is upregulated by both sub-lethal and lethal p53-activating stress, but LRP1 protein is only elevated under sub-lethal stress. Lethal stress induces p53-regulated miRNAs (miR-103 and miR-107) that suppress LRP1 translation, resulting in reduced LRP1 protein and cell death. This constitutes a negative feedback loop.","method":"p53 target gene identification, miRNA overexpression, LRP1 transcript and protein measurement under different stress levels, miR-103/107 functional assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct p53 target identification, miRNA-based translational repression demonstrated with functional consequences, single lab","pmids":["30089260"],"is_preprint":false},{"year":2019,"finding":"APOE4-mediated amyloid-β (Aβ) pathology depends on neuronal LRP1. Neuronal LRP1 deficiency in APP/PS1/APOE4 mice reversed APOE4-dependent increases in Aβ deposition and insoluble Aβ40/Aβ42. LRP1 deficiency increased detergent-soluble apoE4 levels, which may contribute to inhibition of Aβ deposition. The data establish that apoE4 exacerbates Aβ pathology through a mechanism requiring neuronal LRP1.","method":"Neuronal LRP1 conditional knockout crossed with APP/PS1 and APOE3/4 targeted replacement mice, amyloid plaque quantification, Aβ ELISA, apoE level measurement","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — triple-cross genetic model, APOE3 vs APOE4 comparison, multiple Aβ readouts, APOE genotype-dependent mechanism","pmids":["30741718"],"is_preprint":false},{"year":2019,"finding":"Extracellular HSP90α and clusterin synergistically promote breast cancer EMT and metastasis via LRP1. Clusterin participates in eHsp90α-LRP1 complex formation (demonstrated by proximity ligation assay and co-IP) and enhances eHsp90α binding affinity to LRP1, potentiating AKT, ERK, and NF-κB activation and EMT.","method":"Proximity ligation assay, co-immunoprecipitation, in vitro cell migration/invasion assays, in vivo metastasis model, AKT/ERK/NF-κB activation assays","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — PLA and co-IP demonstrating trimeric complex, LRP1 as mediator with in vivo validation, single lab","pmids":["31273033"],"is_preprint":false},{"year":2020,"finding":"LRP1 controls the endocytosis of tau and its subsequent neuronal spread. LRP1 knockdown significantly reduced tau uptake in H4 neuroglioma cells and iPSC-derived neurons. The interaction between tau and LRP1 is mediated by lysine residues in the microtubule-binding repeat region of tau. Downregulation of LRP1 in a mouse model of tau spread effectively reduced tau propagation between neurons.","method":"LRP1 knockdown (siRNA), iPSC-derived neurons, fluorescence-based tau uptake assay, in vivo mouse tau spread model (AAV-mediated), lysine residue mapping","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple cell systems, in vivo mouse model, specific interaction domain mapping (lysine residues), replicated across cell types and in vivo","pmids":["32296178"],"is_preprint":false},{"year":2020,"finding":"LRP1 mutation in cardiac neural crest cells (CNCs) causes congenital heart defects by perturbing outflow tract lengthening. Lrp1 missense mutant (C4232R) and CNC-specific conditional deletion both reproduce atrioventricular septal defects and double outlet right ventricle. Mutant LRP1 is retained in the ER, reducing LRP1 surface expression and impairing cell motility and focal adhesion turnover. Loss of LRP1 in CNCs perturbs Wnt and other signaling pathways.","method":"Knock-in mouse model (C4232R missense), CNC-specific conditional Lrp1 deletion, outflow tract morphometry, cushion explant migration assay, gene expression analysis, ER retention assay, focal adhesion turnover assay","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in and conditional KO models recapitulate phenotype, ER retention mechanism established, cell motility and signaling mechanistically linked","pmids":["32546759"],"is_preprint":false},{"year":2021,"finding":"RVFV glycoprotein (Gn) directly binds to specific Lrp1 clusters in a glycosylation-independent manner, establishing Lrp1 as a host entry factor for Rift Valley fever virus. Murine RAP domain 3 (mRAPD3) and anti-Lrp1 antibodies neutralize RVFV infection in diverse cell lines, and mRAPD3 treatment protects mice from lethal RVFV. A mutant mRAPD3 with weak Lrp1 binding failed to protect.","method":"Genome-wide CRISPR screen, direct binding assay (Gn to Lrp1 clusters), neutralization assays with RAP domain 3 and anti-Lrp1 antibodies, in vivo mouse protection study with mRAPD3","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — CRISPR screen identification, direct binding assay, multiple neutralization approaches, in vivo protection with structure-function (mutant mRAPD3), genome-wide validation","pmids":["34559985"],"is_preprint":false},{"year":2021,"finding":"Endothelial LRP1 protects against neurodegeneration by blocking the cyclophilin A-MMP-9 pathway. LRP1 inactivation from mouse endothelium causes a self-autonomous activation of cyclophilin A-MMP-9 in endothelium, leading to loss of tight junctions and blood-brain barrier breakdown, followed by neuron loss and cognitive deficits. Cyclophilin A inhibition in endothelial LRP1-KO mice restored BBB integrity and reversed neuronal loss. Endothelial-specific LRP1 gene therapy reversed the phenotype.","method":"Endothelial-specific LRP1 knockout mice, cyclophilin A-MMP-9 pathway assays, tight junction protein quantification, BBB integrity assays, behavioral tests, gene therapy rescue, cyclophilin A inhibitor treatment","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — endothelial-specific KO, pathway inhibitor rescue, gene therapy rescue, multiple readouts (BBB, neurons, behavior), two independent rescue strategies","pmids":["33533918"],"is_preprint":false},{"year":2021,"finding":"Brain endothelial LRP1 ablation causes protease-mediated tight junction degradation, P-glycoprotein reduction, and loss of blood-brain barrier integrity, confirming LRP1's role in maintaining BBB structural integrity in CNS endothelium specifically.","method":"CNS endothelial-specific conditional Lrp1 knockout (Slco1c1-CreERT2), tight junction protein analysis, P-gp measurement, BBB permeability assays","journal":"Fluids and barriers of the CNS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CNS-specific conditional KO, multiple BBB readouts, single lab replicating and extending prior findings","pmids":["34147102"],"is_preprint":false},{"year":2022,"finding":"LRP1 is a neuronal receptor for α-synuclein uptake and spread. LRP1 knockout in human iPSC-derived neurons significantly reduced uptake of monomeric and oligomeric α-Syn, and to a lesser extent PFF uptake. Blocking lysine residues on α-Syn decreased its LRP1-mediated uptake, and the N-terminus of α-Syn was critical for LRP1-mediated internalization. Neuronal Lrp1 conditional KO in mice significantly reduced α-Syn spread in the brain.","method":"CRISPR/Cas9 LRP1-KO iPSC-derived neurons, flow cytometry uptake assay, lysine capping with sulfo-NHS acetate, N-terminus deletion, neuronal Lrp1 conditional KO mouse model with AAV-based spread assay","journal":"Molecular neurodegeneration","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO in human neurons, multiple α-Syn species tested, specific domain mapping (lysine, N-terminus), in vivo spread model in conditional KO mice","pmids":["36056345"],"is_preprint":false},{"year":2022,"finding":"OROV (Oropouche orthobunyavirus) uses LRP1 for efficient cellular entry. VSV expressing OROV glycoproteins bound to the LRP1 ectodomain in vitro. RAP treatment and recombinant LRP1 ectodomain truncations reduced OROV infection. RAP treatment of mice reduced tissue viral load and improved survival from lethal infection.","method":"Lrp1-deficient cells (multiple species), in vitro binding assay (VSV-OROV to LRP1 ectodomain), RAP inhibition, recombinant LRP1 ectodomain competition, in vivo mouse protection study","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct binding assay, multiple cell line systems, in vivo protection, mechanistic connection to RVFV entry via same receptor","pmids":["35939689"],"is_preprint":false},{"year":2022,"finding":"Extracellular HMGB1 impairs macrophage-mediated efferocytosis by suppressing Rab43, which is required for anterograde transport of CD91 (LRP1) from the cytoplasm to the cell surface. Rab43 directly interacts with CD91 to mediate its intracellular trafficking. Rab43 KO delays inflammation resolution and aggravates lung damage in ALI mice.","method":"BMDM efferocytosis assay, Rab43 knockdown/KO, CD91 surface transport assay, co-immunoprecipitation (Rab43-CD91), confocal microscopy, in vivo ALI mouse model","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP identifying Rab43-CD91 interaction, Rab43 KO with CD91 trafficking defect, in vivo validation, single lab","pmids":["35392093"],"is_preprint":false},{"year":2023,"finding":"ANKS1A associates with the NPXY motifs of LRP1 and facilitates transport of LRP1 from the endoplasmic reticulum to the cell surface. Endothelial ANKS1A deficiency reduces cell surface LRP1 levels and impairs Aβ clearance across the BBB. In an AD mouse model, ANKS1A deficiency exacerbates Aβ pathology and cognitive impairment, reversible by endothelial-specific ANKS1A gene therapy.","method":"Co-immunoprecipitation (ANKS1A-LRP1 NPXY motifs), endothelial ANKS1A KO mice, surface LRP1 quantification, Aβ clearance assay, iPSC-derived BBB with ANKS1A KO or rs6930932 variant, AD mouse model gene therapy rescue","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — co-IP with specific domain (NPXY), KO with surface trafficking defect, in vivo AD model, human iPSC-derived BBB validation, gene therapy rescue","pmids":["38123547"],"is_preprint":false},{"year":2023,"finding":"LRP1 is identified as an entry factor for SFTS virus. SFTSV glycoprotein Gn interacts with LRP1 CLI and CLII domains (demonstrated by co-IP and surface plasmon resonance). LRP1 knockdown/knockout attenuates SFTSV infection. LRP1 antagonists and neutralizing antibodies reduce SFTSV infection, and LRP1-neutralizing antibody treatment in mice reduces viral load and improves survival.","method":"Genome-wide CRISPR knockout screen, co-immunoprecipitation, surface plasmon resonance (SPR), siRNA knockdown, neutralizing antibody treatment in cells and mice","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — CRISPR screen, SPR direct binding assay with domain specificity, in vivo mouse protection, multiple validation approaches","pmids":["40301361"],"is_preprint":false},{"year":2024,"finding":"Astrocytic LRP1 promotes astrocyte-to-neuron mitochondria transfer by suppressing glucose uptake, glycolysis, and lactate production, thereby reducing ARF1 lactylation. Suppression of astrocytic LRP1 reduced mitochondria transfer into damaged neurons and worsened ischemia-reperfusion injury. This identifies LRP1 as a regulator of lactate-ARF1 lactylation signaling in astrocytes.","method":"Astrocyte-specific LRP1 manipulation, glycolysis/lactate production measurement, ARF1 lactylation assays, mitochondria transfer assays, mouse ischemia-reperfusion model, CSF lactate measurement in human stroke patients","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic pathway (LRP1→glycolysis→lactate→ARF1 lactylation→mitochondria transfer) established in cells and in vivo, human patient correlation","pmids":["38906140"],"is_preprint":false},{"year":2024,"finding":"PCSK9 promotes breast cancer metastasis by targeting tumoral LRP1 receptors, which represses metastasis-suppressing genes XAF1 and USP18. Host PCSK9 enhances metastatic proliferative competence in the lung via LRP1. Antibody-mediated therapeutic inhibition of PCSK9 suppresses breast cancer metastasis in multiple models.","method":"Genetic modeling of PCSK9 gain-of-function SNV in mice, host PCSK9 deletion models, LRP1 receptor identification as PCSK9 target, XAF1/USP18 gene expression analysis, anti-PCSK9 antibody treatment models","journal":"Cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple mouse models, LRP1 identified as downstream target with gene expression readout, single lab","pmids":["39657676"],"is_preprint":false},{"year":2024,"finding":"The VWF-A1 domain binds to LRP1 clusters II and IV via a conserved cluster of lysine residues (K1405-K1408). Alanine mutagenesis of this cluster significantly attenuated VWF binding to both LRP1 clusters II and IV, reduced intracellular degradation, and prolonged VWF in vivo clearance. The aptamer BT200 blocks this K1405-K1408/LRP1 interaction, attenuating macrophage-mediated VWF clearance.","method":"Alanine mutagenesis of VWF-K1405-K1408, ELISA and SPR binding to LRP1 clusters II and IV, in vivo VWF clearance experiments, BT200 aptamer competition assay, HEK-LRP1 cell binding assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis with direct binding assay (SPR/ELISA), in vivo clearance validation, specific LRP1 cluster mapping, aptamer competition confirms site specificity","pmids":["38996211"],"is_preprint":false},{"year":2002,"finding":"LRP1 is phosphorylated on both serine and tyrosine residues; tyrosine-phosphorylated LRP1 specifically associates with the cellular docking protein Shc, implicating LRP1 in signal transduction and suggesting that ligand internalization is regulated by phosphorylation.","method":"Phosphorylation assays, co-immunoprecipitation of phospho-LRP1 with Shc","journal":"Trends in cardiovascular medicine","confidence":"Low","confidence_rationale":"Tier 3 / Weak — review summarizing prior findings on LRP1 phosphorylation and Shc association without new primary data","pmids":["12069755"],"is_preprint":false},{"year":2016,"finding":"LRP1 activities (endocytosis and cell-signaling) compartmentalize into distinct plasma membrane microdomains. In neuron-like cells, LRP1 distributes into lipid rafts and non-raft fractions; disruption of lipid rafts blocks LRP1-mediated Src family kinase and ERK1/2 activation and neurite outgrowth/cell growth, without affecting total ligand binding capacity or endocytic activity of LRP1.","method":"Lipid raft fractionation, methyl-β-cyclodextrin and fumonisin B1 treatment, ERK1/2 and Src kinase activation assays, neurite outgrowth assays, LRP1 ligand binding and endocytosis assays in PC12, N2a, and cerebellar granule neurons","journal":"Molecular and cellular neurosciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — lipid raft disruption with two independent reagents, multiple cell types including primary neurons, orthogonal functional readouts, single lab","pmids":["27565578"],"is_preprint":false},{"year":2022,"finding":"LRP1 promotes infection by multiple RNA viruses (RVFV, sandfly fever Sicilian virus, La Crosse virus, and SARS-CoV-2) by acting at attachment and entry stages. LRP1 inactivation in human cells reduced RVFV RNA levels at entry. LRP1's role in RVFV infection depends on physiological levels of cholesterol and on endocytosis.","method":"Haploid insertion-mutagenesis screen, LRP1 inactivation in human cells, RVFV RNA level measurement at entry, siRNA experiments for SARS-CoV-2 in Calu-3 cells, cholesterol and endocytosis inhibitor experiments","journal":"Life science alliance","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple virus species tested, entry-stage identification, cholesterol/endocytosis dependence established, single lab","pmids":["37072184"],"is_preprint":false},{"year":2023,"finding":"Lrp1 is essential for RVFV hepatic disease in mice. Hepatocyte-specific Lrp1 deletion results in minimal RVFV replication in the liver, longer time to death, and shift toward neurological disease. RVFV infection levels in non-hepatic tissues were unaffected, establishing that Lrp1 in hepatocytes specifically mediates viral hepatic tropism.","method":"Hepatocyte-specific Lrp1 conditional KO mice, RVFV infection, liver viral replication quantification, survival analysis, tissue-specific viral load comparison","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Moderate — hepatocyte-specific conditional KO, tissue-specific viral load comparison, demonstrates organ-specific LRP1 role in disease","pmids":["37450601"],"is_preprint":false},{"year":2019,"finding":"LRP1 mediates midkine (MK) endocytosis in chondrocytes and acts as a translocator delivering MK intracellularly where it forms a complex with nucleolin that interacts with active K-Ras, leading to ERK1/2 activation and cyclin D1 upregulation to promote chondrocyte proliferation.","method":"shRNA knockdown of LRP1, co-immunoprecipitation (MK-nucleolin-K-Ras complex), Western blot for ERK1/2 and cyclin D1, CCK8 proliferation assay, flow cytometry","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP identifying intracellular complex, siRNA functional validation, downstream signaling cascade demonstrated, single lab","pmids":["31639491"],"is_preprint":false},{"year":2022,"finding":"LRP1 heterozygous deficiency causes developmental dysplasia of the hip (DDH) by impairing triradiate chondrocyte differentiation through inhibition of autophagy with β-catenin upregulation. Lrp1 deficiency in mice accelerates triradiate cartilage development timing and reduces chondrogenic ability. Loss of LRP1 decreases autophagy with significant β-catenin upregulation; chondrocyte marker expression is rescued by β-catenin antagonist PNU-74654.","method":"Heterozygous Lrp1 KO mice, Lrp1 knock-in mice (DDH missense variant), in vitro chondrogenesis assay, autophagy measurement, β-catenin assay, PNU-74654 rescue experiment, shRNA in ATDC5 cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO and knock-in models, mechanistic rescue with β-catenin antagonist, in vitro chondrogenesis validation, single lab","pmids":["36067312"],"is_preprint":false},{"year":2025,"finding":"Celastrol directly binds the LRP1 β-chain and abolishes LRP1 interaction with the transcription factor c-Jun in the nucleus, thereby inhibiting CCL2 production by skin fibroblasts, blocking fibroblast-macrophage crosstalk, and ameliorating psoriasis. Fibroblast-specific LRP1 KO mice showed significant reduction in psoriasis-like inflammation.","method":"Direct binding assay (celastrol to LRP1 β-chain), co-IP (LRP1 β-chain with c-Jun), fibroblast-specific LRP1 KO mice, psoriasis murine and cynomolgus monkey models, CCL2 measurement","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding and co-IP identifying nuclear LRP1-c-Jun interaction, fibroblast-specific KO phenotype, in vivo psoriasis models, single lab","pmids":["40177548"],"is_preprint":false}],"current_model":"LRP1 (CD91) is a large multifunctional endocytic and signaling transmembrane receptor that mediates uptake of diverse extracellular ligands (heat shock proteins, ApoE, tau, α-synuclein, prion protein, VWF, transglutaminase, lysosomal enzymes, viral glycoproteins) via clathrin-coated pits in a lipid raft-compartmentalized manner, while simultaneously acting as a cell-signaling hub through ligand-induced and TLR crosstalk-induced phosphorylation (e.g., Y4507) that activates Rab8a/PI3Kγ, NF-κB, MAPK, and Src/ERK pathways; its intracellular domain directly interacts with PPARγ as a transcriptional co-activator, with PARP-1 to regulate cell proliferation, and with c-Jun to modulate gene expression; tissue-specific functions include BBB maintenance by blocking the cyclophilin A-MMP-9 pathway in endothelium, regulation of leptin-receptor signaling and energy homeostasis in the hypothalamus, Schwann cell-axon interactions in the PNS, tau and α-synuclein spread in neurons, and astrocyte-to-neuron mitochondria transfer via suppression of ARF1 lactylation."},"narrative":{"mechanistic_narrative":"LRP1 (CD91) is a large multifunctional endocytic and signaling transmembrane receptor that internalizes a structurally diverse repertoire of extracellular ligands and couples this uptake to intracellular signaling across immune, vascular, metabolic, and neuronal tissues [PMID:11248808, PMID:11290339, PMID:22045000]. As an endocytic receptor it serves antigen-presenting cells by binding heat shock proteins (gp96, hsp90, hsp70, calreticulin) and alpha-2-macroglobulin to deliver chaperoned peptides into the MHC class I cross-presentation pathway, an activity essential for tumor immunity [PMID:11248808, PMID:11290339, PMID:15073331]. The same receptor clears or traffics many additional cargoes — prion protein, transglutaminase, M6P-independent cathepsins, von Willebrand factor, and the spreading neurodegenerative proteins tau and α-synuclein, the latter two engaging LRP1 through lysine residues and N-terminal determinants to drive neuron-to-neuron propagation [PMID:18285446, PMID:17711877, PMID:25786328, PMID:38996211, PMID:32296178, PMID:36056345]. Beyond uptake, LRP1 functions as a signaling hub: ligand engagement and TLR crosstalk trigger phosphorylation (including at Y4507) that recruits Rab8a/PI3Kγ and modulates NF-κB, MAPK, and Akt/mTOR pathways to restrain inflammation in macrophages and microglia [PMID:30208326, PMID:27400748, PMID:22045000], and these endocytic and signaling activities partition into distinct lipid-raft and non-raft membrane microdomains [PMID:27565578]. Its intracellular domain integrates growth-factor and lipid signaling (PDGFRβ, S1P/RAC1, cPLA2/ABCA1) and acts directly in the nucleus as a transcriptional co-activator of PPARγ and as a partner of PARP-1 and c-Jun to control proliferation and gene expression [PMID:25377550, PMID:19718435, PMID:28393867, PMID:26634655, PMID:40177548]. Tissue-specific genetic studies establish LRP1 as a controller of hypothalamic leptin signaling and energy balance, Schwann cell–axon interactions and remyelination, cardiac neural crest outflow-tract development, triradiate chondrocyte differentiation, and endothelial blood-brain barrier maintenance via suppression of the cyclophilin A–MMP-9 pathway [PMID:21264353, PMID:23536074, PMID:32546759, PMID:36067312, PMID:33533918]. In neurodegeneration, neuronal LRP1 is required for APOE4-driven amyloid-β pathology, while its endothelial surface delivery by ANKS1A governs Aβ clearance across the BBB [PMID:30741718, PMID:38123547]. LRP1 is also a broadly exploited viral entry factor, with its ectodomain clusters directly bound by the glycoproteins of Rift Valley fever, Oropouche, and SFTS viruses to mediate attachment and tissue tropism [PMID:34559985, PMID:35939689, PMID:40301361, PMID:37450601].","teleology":[{"year":2000,"claim":"Established that CD91/LRP1 is the direct cell-surface receptor through which heat shock protein chaperones deliver peptides for MHC class I cross-presentation, defining LRP1's role in adaptive immunity.","evidence":"Direct binding, alpha-2-macroglobulin competitive inhibition, and antibody blockade of gp96 re-presentation in macrophages","pmids":["11248808"],"confidence":"High","gaps":["Did not define the structural binding interface on LRP1 for gp96","Did not address whether other HSPs use the same receptor"]},{"year":2001,"claim":"Generalized LRP1 as a common receptor for multiple HSPs and alpha-2-macroglobulin feeding into the proteasome/TAP-dependent presentation pathway, broadening its immunological scope.","evidence":"Uptake and re-presentation assays with gp96, hsp90, hsp70, calreticulin and alpha-2M; proteasome/TAP inhibitor and TAP-deficient cell studies","pmids":["11290339","11290775"],"confidence":"High","gaps":["Whether distinct HSPs use overlapping or distinct LRP1 binding sites unresolved","alpha-2M adjuvant function shown in a single lab"]},{"year":2004,"claim":"Demonstrated LRP1 is functionally necessary, not merely correlative, for HSP-peptide presentation and tumor immunity, converting a binding observation into a causal requirement.","evidence":"siRNA knockdown with expression recovery and in vivo anti-CD91 antisera abrogating tumor immunity","pmids":["15073331"],"confidence":"High","gaps":["Did not resolve the intracellular routing of HSP-peptide complexes after LRP1 uptake"]},{"year":2007,"claim":"Showed LRP1 mediates constitutive endocytosis and lysosomal degradation of cell-surface transglutaminase, extending its function to control of adhesion and matrix crosslinking.","evidence":"In vitro binding, co-IP, LRP1-deficient cells, surface expression and ligand-stimulated endocytosis assays","pmids":["17711877"],"confidence":"High","gaps":["Binding site on LRP1 not mapped","Physiological context of transglutaminase regulation in vivo not tested"]},{"year":2008,"claim":"Identified LRP1 as required for prion protein trafficking and surface delivery, linking the receptor to neuronal protein handling with nanomolar binding affinity.","evidence":"siRNA knockdown, ER co-IP, in vitro binding affinity measurement, surface PrPC quantification","pmids":["18285446"],"confidence":"High","gaps":["Did not establish consequences for prion disease pathogenesis","In vivo relevance not tested"]},{"year":2011,"claim":"Defined LRP1 as a signaling receptor (not only endocytic), showing HSP-LRP1 engagement triggers receptor phosphorylation and NF-κB-driven APC maturation and Th-subset priming.","evidence":"CD91 phosphorylation and NF-κB assays, cytokine profiling, Th cell priming with multiple HSPs","pmids":["22045000"],"confidence":"High","gaps":["Phosphorylation sites not mapped in this work","Adaptors coupling phospho-LRP1 to NF-κB not identified"]},{"year":2011,"claim":"Connected LRP1 to systemic physiology by showing it binds leptin/leptin receptor and is required for hypothalamic leptin signaling and energy homeostasis.","evidence":"Brain- and hypothalamus-specific Lrp1 conditional KO, direct binding, leptin receptor phosphorylation and Stat3 activation assays","pmids":["21264353"],"confidence":"High","gaps":["Molecular mechanism linking LRP1 to LepR phosphorylation not fully resolved","Peripheral versus central contributions not dissected"]},{"year":2013,"claim":"Established cell-type-specific developmental and immune roles — LRP1 in Schwann cells for myelination/repair and in myeloid cells for NF-κB-dependent migration and chemokine control.","evidence":"Schwann-cell-specific and myeloid-specific conditional KO with injury, behavior, tumor models, and neutralizing antibody/NF-κB inhibitor rescue","pmids":["23536074","23633492"],"confidence":"High","gaps":["Ligands driving Schwann cell LRP1 signaling not defined","Link between endocytic and NF-κB-regulatory functions unresolved"]},{"year":2014,"claim":"Revealed that the LRP1 intracellular domain integrates S1P and PDGF-BB signaling to constrain RAC1-driven migration, explaining its essential role in vascular mural cell development.","evidence":"Genetically engineered mice with lethal vascular phenotype, S1P/RAC1/PDGF-BB signaling and migration assays, ICD analysis","pmids":["25377550"],"confidence":"High","gaps":["Direct ICD-effector interactions not biochemically resolved"]},{"year":2015,"claim":"Showed LRP1 provides an M6P-independent secretion-recapture route for lysosomal enzyme targeting, broadening its endocytic substrate range to cathepsins.","evidence":"SILAC lysosomal proteomics, LRP1/LDLR-deficient fibroblasts, LRP1 inhibitor and cathepsin secretion assays","pmids":["25786328"],"confidence":"Medium","gaps":["Single lab; binding determinants on cathepsins not mapped","Relative contribution versus LDLR not quantified"]},{"year":2017,"claim":"Demonstrated a nuclear transcriptional function: the LRP1 ICD interacts with PPARγ as a co-activator, linking the receptor to endothelial metabolic gene programs.","evidence":"Endothelial-specific Lrp1 KO with metabolic phenotyping, co-IP of LRP1 ICD with PPARγ, transcriptional co-activation assays","pmids":["28393867"],"confidence":"High","gaps":["Mechanism of ICD nuclear translocation not defined","Direct DNA target genes not enumerated"]},{"year":2018,"claim":"Mapped a TLR-driven phosphorylation event (Y4507) that recruits Rab8a/PI3Kγ to reprogram macrophage inflammatory output, mechanistically defining LRP1 as an anti-inflammatory signaling node.","evidence":"CRISPR KO, Y4507 phosphorylation and Rab8a activation assays, recruitment co-IP, cytokine profiling, comparison to Rab8a/PI3Kγ-null phenotypes","pmids":["30208326"],"confidence":"High","gaps":["Kinase phosphorylating Y4507 not identified","Relationship to lipid-raft compartmentalization of signaling not addressed"]},{"year":2018,"claim":"Placed LRP1 in a p53-controlled stress circuit, where lethal stress represses LRP1 translation via miR-103/107, establishing a negative feedback loop tied to cell death.","evidence":"p53 target identification, miRNA overexpression, transcript/protein measurement under graded stress","pmids":["30089260"],"confidence":"Medium","gaps":["Single lab; functional contribution of LRP1 loss to the death decision not isolated"]},{"year":2019,"claim":"Identified LRP1 partners controlling proliferation and signaling — PARP-1 (endothelial cell cycle), midkine/nucleolin/K-Ras (chondrocyte ERK signaling), and lipid-homeostasis pathways (cPLA2/ABCA1, adipogenesis).","evidence":"Co-IP, endothelial KO with retinopathy model, shRNA, downstream signaling and lipid/differentiation assays","pmids":["26634655","31639491","19718435","19823686"],"confidence":"High","gaps":["Whether these intracellular partnerships share a common ICD-dependent mechanism unresolved","Some lipid-homeostasis findings are single-lab Medium evidence"]},{"year":2016,"claim":"Clarified that LRP1 endocytic versus signaling activities are spatially segregated into distinct membrane microdomains, with lipid rafts required selectively for Src/ERK signaling.","evidence":"Lipid raft fractionation, MβCD/fumonisin B1 disruption, kinase activation and neurite/endocytosis assays across neuronal cell types","pmids":["27565578"],"confidence":"Medium","gaps":["Molecular determinants partitioning LRP1 between microdomains not identified"]},{"year":2020,"claim":"Established neuronal LRP1 as the receptor mediating tau and (later) α-synuclein uptake and propagation, identifying lysine residues and N-terminal determinants as the engagement sites — a therapeutic target for neurodegenerative spread.","evidence":"siRNA/CRISPR KO in H4 cells and iPSC-derived neurons, fluorescent uptake assays, lysine/N-terminus mapping, in vivo AAV tau/α-Syn spread models","pmids":["32296178","36056345"],"confidence":"High","gaps":["Structural basis of lysine-dependent binding not solved","Whether the same LRP1 sites bind tau and α-Syn unresolved"]},{"year":2019,"claim":"Linked LRP1 genetically to APOE4-driven amyloid-β pathology, showing neuronal LRP1 is required for the APOE4-dependent worsening of Aβ deposition.","evidence":"Neuronal LRP1 conditional KO crossed with APP/PS1 and APOE3/4 replacement mice, plaque quantification, Aβ ELISA, apoE measurement","pmids":["30741718"],"confidence":"High","gaps":["Whether the effect operates via apoE clearance, Aβ clearance, or both not fully separated"]},{"year":2020,"claim":"Defined LRP1's developmental requirement in cardiac neural crest, where a missense (C4232R) variant causes ER retention, reduced surface receptor, and outflow-tract congenital heart defects.","evidence":"Knock-in missense and CNC-specific conditional KO mice, outflow morphometry, ER retention, migration and focal-adhesion assays","pmids":["32546759"],"confidence":"High","gaps":["Precise signaling pathway (Wnt and others) downstream of LRP1 in CNCs not fully resolved"]},{"year":2021,"claim":"Established endothelial LRP1 as a guardian of blood-brain barrier integrity by suppressing the cyclophilin A–MMP-9 pathway, with two independent rescue strategies confirming causality.","evidence":"Endothelial-specific KO, cyclophilin A inhibitor and endothelial LRP1 gene-therapy rescue, BBB, neuron loss and behavior readouts; CNS-endothelial KO replicating tight junction/P-gp loss","pmids":["33533918","34147102"],"confidence":"High","gaps":["How LRP1 represses endothelial cyclophilin A mechanistically not fully defined"]},{"year":2021,"claim":"Identified LRP1 as a direct, broadly used viral entry factor, with bunyavirus glycoproteins binding specific ectodomain clusters and RAP/anti-LRP1 reagents conferring in vivo protection.","evidence":"Genome-wide CRISPR and haploid screens, direct glycoprotein-cluster binding (SPR/co-IP), RAP and neutralizing antibody protection in cells and mice for RVFV, OROV, SFTSV and others","pmids":["34559985","35939689","35939689","40301361","37072184"],"confidence":"High","gaps":["Structural details of glycoprotein-cluster recognition vary by virus","Whether endogenous ligands compete with viral glycoproteins not resolved"]},{"year":2023,"claim":"Resolved how surface LRP1 abundance is set by dedicated trafficking factors — ANKS1A binding NPXY motifs and Rab43 mediating anterograde transport — with ANKS1A loss impairing BBB Aβ clearance.","evidence":"Co-IP (ANKS1A-NPXY; Rab43-CD91), endothelial ANKS1A KO and Rab43 KO, surface LRP1/Aβ clearance and efferocytosis assays, AD and ALI mouse models, gene therapy rescue","pmids":["38123547","35392093"],"confidence":"High","gaps":["Rab43-CD91 trafficking validated in single lab","Interplay between ANKS1A and Rab43 in the same transport step not tested"]},{"year":2023,"claim":"Demonstrated organ-specific viral disease driven by LRP1, with hepatocyte LRP1 dictating RVFV hepatic tropism and severity.","evidence":"Hepatocyte-specific Lrp1 conditional KO, RVFV liver replication and survival, tissue-specific viral load comparison","pmids":["37450601"],"confidence":"High","gaps":["Why hepatocyte LRP1 dominates tropism over other tissues not mechanistically explained"]},{"year":2024,"claim":"Uncovered new disease-relevant axes — astrocytic LRP1 enabling mitochondria transfer via lactate/ARF1 lactylation control, and tumoral LRP1 as a PCSK9 target repressing metastasis-suppressor genes.","evidence":"Astrocyte-specific LRP1 manipulation with glycolysis/lactylation/mitochondria-transfer assays and ischemia-reperfusion model with human CSF correlation; PCSK9 gain/loss mouse models with XAF1/USP18 readout and anti-PCSK9 therapy","pmids":["38906140","39657676"],"confidence":"High","gaps":["Direct molecular link between LRP1 and ARF1 lactylation incompletely defined","How PCSK9 engagement of LRP1 represses XAF1/USP18 not mechanistically resolved"]},{"year":2024,"claim":"Mapped VWF clearance to a defined LRP1 interaction, with VWF-A1 lysines K1405-K1408 binding LRP1 clusters II and IV, and showed an aptamer can block macrophage-mediated VWF clearance.","evidence":"Alanine mutagenesis, ELISA/SPR cluster binding, in vivo VWF clearance, BT200 aptamer competition","pmids":["38996211"],"confidence":"High","gaps":["Structural basis of dual cluster II/IV engagement not solved"]},{"year":2025,"claim":"Defined a nuclear LRP1-c-Jun interaction controlling fibroblast CCL2 production and fibroblast-macrophage crosstalk in psoriasis, providing a druggable LRP1 β-chain interface.","evidence":"Direct celastrol-β-chain binding, co-IP of β-chain with c-Jun, fibroblast-specific LRP1 KO, murine and primate psoriasis models","pmids":["40177548"],"confidence":"Medium","gaps":["Single lab; how the β-chain reaches the nucleus to engage c-Jun not established"]},{"year":null,"claim":"It remains unresolved how LRP1's many functions — endocytosis, membrane signaling, and nuclear transcriptional partnerships (PPARγ, PARP-1, c-Jun) — are mechanistically coordinated, including the cleavage/translocation events that generate signaling fragments and the structural rules governing its promiscuous ligand recognition.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unifying structural model for ligand-cluster specificity across diverse cargoes","Pathway from membrane LRP1 to ICD nuclear function not biochemically resolved","Kinases and adaptors coupling LRP1 phosphorylation to specific outputs incompletely defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[0,1,3,14,18,26,31,38]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[28,32,35,41,42]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[11,22,8,17]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[21,45,19]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[20,13]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,22,40,4]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[4,27,34]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[14,18]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[21,45]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[9,33]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,3,11,20,13]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[4,14,18,38]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[22,17,11,8]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[24,28,32,35,37]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[15,16,36,21]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[12,17,27,44]},{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[33,34]}],"complexes":[],"partners":["LEPR","PPARG","PARP1","JUN","SHC1","RAB8A","ANKS1A","RAB43"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q07954","full_name":"Prolow-density lipoprotein receptor-related protein 1","aliases":["Alpha-2-macroglobulin receptor","A2MR","Apolipoprotein E receptor","APOER"],"length_aa":4544,"mass_kda":504.6,"function":"Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells (PubMed:11907044, PubMed:12713657). Required for early embryonic development (By similarity). Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. Acts as an LRPAP1 alpha-2-macroglobulin receptor (PubMed:1702392, PubMed:26142438). Acts as TAU/MAPT receptor and controls the endocytosis of TAU/MAPT as well as its subsequent spread (PubMed:32296178). May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission (PubMed:12888553). Also acts as a receptor for IGFBP3 to mediate cell growth inhibition (PubMed:9252371) (Microbial infection) Functions as a receptor for Pseudomonas aeruginosa exotoxin A","subcellular_location":"Golgi outpost; Cytoplasm, cytoskeleton, microtubule organizing center","url":"https://www.uniprot.org/uniprotkb/Q07954/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LRP1","classification":"Not Classified","n_dependent_lines":13,"n_total_lines":1208,"dependency_fraction":0.01076158940397351},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LRP1","total_profiled":1310},"omim":[{"mim_id":"620690","title":"DEVELOPMENTAL DYSPLASIA OF THE HIP 3; DDH3","url":"https://www.omim.org/entry/620690"},{"mim_id":"620553","title":"COILED-COIL DOMAIN-CONTAINING PROTEIN 93; CCDC93","url":"https://www.omim.org/entry/620553"},{"mim_id":"617986","title":"LOW DENSITY LIPOPROTEIN RECEPTOR CLASS A DOMAIN-CONTAINING PROTEIN 3; LDLRAD3","url":"https://www.omim.org/entry/617986"},{"mim_id":"616701","title":"COMM DOMAIN-CONTAINING PROTEIN 4; COMMD4","url":"https://www.omim.org/entry/616701"},{"mim_id":"614375","title":"AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 4; AAA4","url":"https://www.omim.org/entry/614375"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nucleoli","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"adipose tissue","ntpm":102.4}],"url":"https://www.proteinatlas.org/search/LRP1"},"hgnc":{"alias_symbol":["LRP","CD91","LRP1A","APOER","IGFBP3R1","IGFBP-3R"],"prev_symbol":["APR","A2MR"]},"alphafold":{"accession":"Q07954","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07954","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q07954-2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q07954-2-F1-predicted_aligned_error_v6.png","plddt_mean":79.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LRP1","jax_strain_url":"https://www.jax.org/strain/search?query=LRP1"},"sequence":{"accession":"Q07954","fasta_url":"https://rest.uniprot.org/uniprotkb/Q07954.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q07954/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07954"}},"corpus_meta":[{"pmid":"11290339","id":"PMC_11290339","title":"CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin.","date":"2001","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11290339","citation_count":840,"is_preprint":false},{"pmid":"11248808","id":"PMC_11248808","title":"CD91: a receptor for heat shock protein gp96.","date":"2000","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11248808","citation_count":516,"is_preprint":false},{"pmid":"32296178","id":"PMC_32296178","title":"LRP1 is a master regulator of tau uptake and spread.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296178","citation_count":435,"is_preprint":false},{"pmid":"28381441","id":"PMC_28381441","title":"Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies.","date":"2017","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/28381441","citation_count":242,"is_preprint":false},{"pmid":"38906140","id":"PMC_38906140","title":"Astrocytic LRP1 enables mitochondria transfer to neurons and mitigates brain ischemic stroke by suppressing ARF1 lactylation.","date":"2024","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38906140","citation_count":199,"is_preprint":false},{"pmid":"22045000","id":"PMC_22045000","title":"CD91-dependent programming of T-helper cell responses following heat shock protein immunization.","date":"2011","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/22045000","citation_count":168,"is_preprint":false},{"pmid":"15073331","id":"PMC_15073331","title":"Essential role of CD91 in re-presentation of gp96-chaperoned peptides.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15073331","citation_count":168,"is_preprint":false},{"pmid":"30741718","id":"PMC_30741718","title":"APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1.","date":"2019","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/30741718","citation_count":132,"is_preprint":false},{"pmid":"20610799","id":"PMC_20610799","title":"Inflammatory mediators promote production of shed LRP1/CD91, which regulates cell signaling and cytokine expression by macrophages.","date":"2010","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/20610799","citation_count":113,"is_preprint":false},{"pmid":"16645988","id":"PMC_16645988","title":"Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus.","date":"2006","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/16645988","citation_count":112,"is_preprint":false},{"pmid":"34559985","id":"PMC_34559985","title":"Lrp1 is a host entry factor for Rift Valley fever virus.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/34559985","citation_count":111,"is_preprint":false},{"pmid":"33533918","id":"PMC_33533918","title":"Endothelial LRP1 protects against neurodegeneration by blocking cyclophilin A.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33533918","citation_count":104,"is_preprint":false},{"pmid":"22822085","id":"PMC_22822085","title":"Low-density lipoprotein receptor-related protein-1 (LRP1) mediates autophagy and apoptosis caused by Helicobacter pylori VacA.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22822085","citation_count":100,"is_preprint":false},{"pmid":"20558745","id":"PMC_20558745","title":"Secreted heat shock protein 90alpha induces colorectal cancer cell invasion through CD91/LRP-1 and NF-kappaB-mediated integrin alphaV expression.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20558745","citation_count":98,"is_preprint":false},{"pmid":"18285446","id":"PMC_18285446","title":"LRP1 controls biosynthetic and endocytic trafficking of neuronal prion protein.","date":"2008","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/18285446","citation_count":92,"is_preprint":false},{"pmid":"36056345","id":"PMC_36056345","title":"LRP1 is a neuronal receptor for α-synuclein uptake and spread.","date":"2022","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/36056345","citation_count":88,"is_preprint":false},{"pmid":"25937287","id":"PMC_25937287","title":"Antisense RNA controls LRP1 Sense transcript expression through interaction with a chromatin-associated protein, HMGB2.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25937287","citation_count":87,"is_preprint":false},{"pmid":"16920480","id":"PMC_16920480","title":"CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes.","date":"2006","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/16920480","citation_count":81,"is_preprint":false},{"pmid":"21264353","id":"PMC_21264353","title":"Lipoprotein receptor LRP1 regulates leptin signaling and energy homeostasis in the adult central nervous system.","date":"2011","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/21264353","citation_count":76,"is_preprint":false},{"pmid":"23936774","id":"PMC_23936774","title":"LRP-1: a checkpoint for the extracellular matrix proteolysis.","date":"2013","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/23936774","citation_count":75,"is_preprint":false},{"pmid":"30208326","id":"PMC_30208326","title":"TLR Crosstalk Activates LRP1 to Recruit Rab8a and PI3Kγ for Suppression of Inflammatory Responses.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30208326","citation_count":72,"is_preprint":false},{"pmid":"23633492","id":"PMC_23633492","title":"Myeloid cell receptor LRP1/CD91 regulates monocyte recruitment and angiogenesis in tumors.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23633492","citation_count":70,"is_preprint":false},{"pmid":"22412839","id":"PMC_22412839","title":"Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22412839","citation_count":70,"is_preprint":false},{"pmid":"23536074","id":"PMC_23536074","title":"Schwann cell LRP1 regulates remak bundle ultrastructure and axonal interactions to prevent neuropathic pain.","date":"2013","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23536074","citation_count":67,"is_preprint":false},{"pmid":"31273033","id":"PMC_31273033","title":"Extracellular Hsp90α and clusterin synergistically promote breast cancer epithelial-to-mesenchymal transition and metastasis via LRP1.","date":"2019","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/31273033","citation_count":65,"is_preprint":false},{"pmid":"27400748","id":"PMC_27400748","title":"LRP1 expression in microglia is protective during CNS autoimmunity.","date":"2016","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/27400748","citation_count":62,"is_preprint":false},{"pmid":"23963646","id":"PMC_23963646","title":"Low density receptor-related protein 1 (LRP1) promotes anti-inflammatory phenotype in murine macrophages.","date":"2013","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/23963646","citation_count":58,"is_preprint":false},{"pmid":"35939689","id":"PMC_35939689","title":"Oropouche orthobunyavirus infection is mediated by the cellular host factor Lrp1.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35939689","citation_count":57,"is_preprint":false},{"pmid":"11290775","id":"PMC_11290775","title":"Adjuvanticity of alpha 2-macroglobulin, an independent ligand for the heat shock protein receptor CD91.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11290775","citation_count":57,"is_preprint":false},{"pmid":"28393867","id":"PMC_28393867","title":"Endothelial LRP1 regulates metabolic responses by acting as a co-activator of PPARγ.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28393867","citation_count":56,"is_preprint":false},{"pmid":"19823686","id":"PMC_19823686","title":"LRP1 receptor controls adipogenesis and is up-regulated in human and mouse obese adipose tissue.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19823686","citation_count":54,"is_preprint":false},{"pmid":"12069755","id":"PMC_12069755","title":"Phosphorylation of LRP1: regulation of transport and signal transduction.","date":"2002","source":"Trends in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12069755","citation_count":52,"is_preprint":false},{"pmid":"25786328","id":"PMC_25786328","title":"Lrp1/LDL Receptor Play Critical Roles in Mannose 6-Phosphate-Independent Lysosomal Enzyme Targeting.","date":"2015","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/25786328","citation_count":52,"is_preprint":false},{"pmid":"17711877","id":"PMC_17711877","title":"Cell-surface transglutaminase undergoes internalization and lysosomal degradation: an essential role for LRP1.","date":"2007","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/17711877","citation_count":51,"is_preprint":false},{"pmid":"26061292","id":"PMC_26061292","title":"LDL Receptor-Related Protein-1 (LRP1) Regulates Cholesterol Accumulation in Macrophages.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26061292","citation_count":50,"is_preprint":false},{"pmid":"26617523","id":"PMC_26617523","title":"The Matricellular Receptor LRP1 Forms an Interface for Signaling and Endocytosis in Modulation of the Extracellular Tumor Environment.","date":"2015","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26617523","citation_count":46,"is_preprint":false},{"pmid":"25514242","id":"PMC_25514242","title":"LRP-1: functions, signaling and implications in kidney and other diseases.","date":"2014","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25514242","citation_count":45,"is_preprint":false},{"pmid":"20716178","id":"PMC_20716178","title":"Direct interaction between CD91 and C1q.","date":"2010","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/20716178","citation_count":43,"is_preprint":false},{"pmid":"25377550","id":"PMC_25377550","title":"The lipoprotein receptor LRP1 modulates sphingosine-1-phosphate signaling and is essential for vascular development.","date":"2014","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25377550","citation_count":43,"is_preprint":false},{"pmid":"23573918","id":"PMC_23573918","title":"Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease.","date":"2013","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/23573918","citation_count":42,"is_preprint":false},{"pmid":"12531796","id":"PMC_12531796","title":"The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected \"true\" long-term nonprogressors.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12531796","citation_count":41,"is_preprint":false},{"pmid":"15948984","id":"PMC_15948984","title":"Activation of dendritic antigen-presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis.","date":"2005","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15948984","citation_count":41,"is_preprint":false},{"pmid":"29262309","id":"PMC_29262309","title":"LRP1: A chameleon receptor of lung inflammation and repair.","date":"2017","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29262309","citation_count":40,"is_preprint":false},{"pmid":"24661974","id":"PMC_24661974","title":"Regulation of LRP-1 expression: make the point.","date":"2014","source":"Pathologie-biologie","url":"https://pubmed.ncbi.nlm.nih.gov/24661974","citation_count":40,"is_preprint":false},{"pmid":"34243608","id":"PMC_34243608","title":"The molecular mechanism of LRP1 in physiological vascular homeostasis and signal transduction pathways.","date":"2021","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/34243608","citation_count":40,"is_preprint":false},{"pmid":"26634655","id":"PMC_26634655","title":"LRP1 Regulates Retinal Angiogenesis by Inhibiting PARP-1 Activity and Endothelial Cell Proliferation.","date":"2015","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26634655","citation_count":40,"is_preprint":false},{"pmid":"21711236","id":"PMC_21711236","title":"Regulation of the urokinase receptor (uPAR) by LDL receptor-related protein-1 (LRP1).","date":"2011","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/21711236","citation_count":39,"is_preprint":false},{"pmid":"37590164","id":"PMC_37590164","title":"Targeted Lysosomal Degradation of Secreted and Cell Surface Proteins through the LRP-1 Pathway.","date":"2023","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/37590164","citation_count":39,"is_preprint":false},{"pmid":"36973740","id":"PMC_36973740","title":"FUT2 inhibits the EMT and metastasis of colorectal cancer by increasing LRP1 fucosylation.","date":"2023","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/36973740","citation_count":38,"is_preprint":false},{"pmid":"19718435","id":"PMC_19718435","title":"LRP1 controls cPLA2 phosphorylation, ABCA1 expression and cellular cholesterol export.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19718435","citation_count":38,"is_preprint":false},{"pmid":"30089260","id":"PMC_30089260","title":"p53 Regulates the Expression of LRP1 and Apoptosis through a Stress Intensity-Dependent MicroRNA Feedback Loop.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30089260","citation_count":38,"is_preprint":false},{"pmid":"34147102","id":"PMC_34147102","title":"Brain endothelial LRP1 maintains blood-brain barrier integrity.","date":"2021","source":"Fluids and barriers of the CNS","url":"https://pubmed.ncbi.nlm.nih.gov/34147102","citation_count":36,"is_preprint":false},{"pmid":"20472562","id":"PMC_20472562","title":"Low density lipoprotein receptor-related protein-1 (LRP1) regulates thrombospondin-2 (TSP2) enhancement of Notch3 signaling.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20472562","citation_count":34,"is_preprint":false},{"pmid":"18292541","id":"PMC_18292541","title":"Phylogenetic conservation of glycoprotein 96 ability to interact with CD91 and facilitate antigen cross-presentation.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18292541","citation_count":33,"is_preprint":false},{"pmid":"29507659","id":"PMC_29507659","title":"LRP1 expression in colon cancer predicts clinical outcome.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29507659","citation_count":31,"is_preprint":false},{"pmid":"25220876","id":"PMC_25220876","title":"Capsaicin-mediated apoptosis of human bladder cancer cells activates dendritic cells via CD91.","date":"2014","source":"Nutrition (Burbank, Los Angeles County, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/25220876","citation_count":31,"is_preprint":false},{"pmid":"30696029","id":"PMC_30696029","title":"Developing LRP1 Agonists into a Therapeutic Strategy in Acute Myocardial Infarction.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30696029","citation_count":30,"is_preprint":false},{"pmid":"27317662","id":"PMC_27317662","title":"LRP1 Protein Deficiency Exacerbates Palmitate-induced Steatosis and Toxicity in Hepatocytes.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27317662","citation_count":29,"is_preprint":false},{"pmid":"25300797","id":"PMC_25300797","title":"Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell motility in human osteosarcoma.","date":"2014","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25300797","citation_count":29,"is_preprint":false},{"pmid":"39657676","id":"PMC_39657676","title":"A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor.","date":"2024","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/39657676","citation_count":28,"is_preprint":false},{"pmid":"16167883","id":"PMC_16167883","title":"Immune function of C1q and its modulators CD91 and CD93.","date":"2005","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16167883","citation_count":28,"is_preprint":false},{"pmid":"37072184","id":"PMC_37072184","title":"Low-density lipoprotein receptor-related protein 1 (LRP1) as an auxiliary host factor for RNA viruses.","date":"2023","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/37072184","citation_count":28,"is_preprint":false},{"pmid":"35680846","id":"PMC_35680846","title":"LDL receptor-related protein 1 (LRP1), a novel target for opening the blood-labyrinth barrier (BLB).","date":"2022","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35680846","citation_count":28,"is_preprint":false},{"pmid":"24947444","id":"PMC_24947444","title":"Placental heme receptor LRP1 correlates with the heme exporter FLVCR1 and neonatal iron status.","date":"2014","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24947444","citation_count":28,"is_preprint":false},{"pmid":"36067312","id":"PMC_36067312","title":"Heterozygous LRP1 deficiency causes developmental dysplasia of the hip by impairing triradiate chondrocytes differentiation due to inhibition of autophagy.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36067312","citation_count":27,"is_preprint":false},{"pmid":"38123547","id":"PMC_38123547","title":"ANKS1A regulates LDL receptor-related protein 1 (LRP1)-mediated cerebrovascular clearance in brain endothelial cells.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38123547","citation_count":27,"is_preprint":false},{"pmid":"37020553","id":"PMC_37020553","title":"Multi-faceted role of LRP1 in the immune system.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37020553","citation_count":27,"is_preprint":false},{"pmid":"30910704","id":"PMC_30910704","title":"LRP1 promotes synthetic phenotype of pulmonary artery smooth muscle cells in pulmonary hypertension.","date":"2019","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/30910704","citation_count":27,"is_preprint":false},{"pmid":"18266273","id":"PMC_18266273","title":"Cellular uptake of C4b-binding protein is mediated by heparan sulfate proteoglycans and CD91/LDL receptor-related protein.","date":"2008","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18266273","citation_count":26,"is_preprint":false},{"pmid":"15161872","id":"PMC_15161872","title":"Expression of LRP1 in retinal pigment epithelial cells and its regulation by growth factors.","date":"2004","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/15161872","citation_count":26,"is_preprint":false},{"pmid":"38950861","id":"PMC_38950861","title":"Novel insights into the multifaceted and tissue-specific roles of the endocytic receptor LRP1.","date":"2024","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38950861","citation_count":25,"is_preprint":false},{"pmid":"35628341","id":"PMC_35628341","title":"Secreted HSP90α-LRP1 Signaling Promotes Tumor Metastasis and Chemoresistance in Pancreatic Cancer.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35628341","citation_count":25,"is_preprint":false},{"pmid":"35392093","id":"PMC_35392093","title":"Extracellular HMGB1 Impairs Macrophage-Mediated Efferocytosis by Suppressing the Rab43-Controlled Cell Surface Transport of CD91.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35392093","citation_count":25,"is_preprint":false},{"pmid":"37036005","id":"PMC_37036005","title":"LRP1 in vascular mural cells modulates cerebrovascular integrity and function in the presence of APOE4.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/37036005","citation_count":24,"is_preprint":false},{"pmid":"38063014","id":"PMC_38063014","title":"Clearance of Neutrophils From ICH-Affected Brain by Macrophages Is Beneficial and Is Assisted by Lactoferrin and CD91.","date":"2023","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/38063014","citation_count":23,"is_preprint":false},{"pmid":"17258834","id":"PMC_17258834","title":"Serpin A1 and CD91 as host instruments against HIV-1 infection: are extracellular antiviral peptides acting as intracellular messengers?","date":"2007","source":"Virus research","url":"https://pubmed.ncbi.nlm.nih.gov/17258834","citation_count":23,"is_preprint":false},{"pmid":"30458112","id":"PMC_30458112","title":"The fibrinolytic factor tPA drives LRP1-mediated melanoma growth and metastasis.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30458112","citation_count":23,"is_preprint":false},{"pmid":"34489478","id":"PMC_34489478","title":"Endothelium-specific depletion of LRP1 improves glucose homeostasis through inducing osteocalcin.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34489478","citation_count":22,"is_preprint":false},{"pmid":"25050192","id":"PMC_25050192","title":"The heat shock protein-CD91 pathway mediates tumor immunosurveillance.","date":"2014","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/25050192","citation_count":21,"is_preprint":false},{"pmid":"30944251","id":"PMC_30944251","title":"CD91 on dendritic cells governs immunosurveillance of nascent, emerging tumors.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/30944251","citation_count":21,"is_preprint":false},{"pmid":"31639491","id":"PMC_31639491","title":"Midkine promotes articular chondrocyte proliferation through the MK-LRP1-nucleolin signaling pathway.","date":"2019","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/31639491","citation_count":21,"is_preprint":false},{"pmid":"32546759","id":"PMC_32546759","title":"Mutation of LRP1 in cardiac neural crest cells causes congenital heart defects by perturbing outflow lengthening.","date":"2020","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/32546759","citation_count":21,"is_preprint":false},{"pmid":"39216548","id":"PMC_39216548","title":"YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/39216548","citation_count":20,"is_preprint":false},{"pmid":"37450601","id":"PMC_37450601","title":"Lrp1 is essential for lethal Rift Valley fever hepatic disease in mice.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37450601","citation_count":20,"is_preprint":false},{"pmid":"15498042","id":"PMC_15498042","title":"The common heat shock protein receptor CD91 is up-regulated on monocytes of advanced melanoma slow progressors.","date":"2004","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15498042","citation_count":20,"is_preprint":false},{"pmid":"27565578","id":"PMC_27565578","title":"The activities of LDL Receptor-related Protein-1 (LRP1) compartmentalize into distinct plasma membrane microdomains.","date":"2016","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/27565578","citation_count":20,"is_preprint":false},{"pmid":"16262727","id":"PMC_16262727","title":"Differential CD91 dependence for calreticulin and Pseudomonas exotoxin-A endocytosis.","date":"2005","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/16262727","citation_count":19,"is_preprint":false},{"pmid":"40177548","id":"PMC_40177548","title":"Celastrol directly targets LRP1 to inhibit fibroblast-macrophage crosstalk and ameliorates psoriasis progression.","date":"2025","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/40177548","citation_count":18,"is_preprint":false},{"pmid":"38996211","id":"PMC_38996211","title":"The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1.","date":"2024","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/38996211","citation_count":18,"is_preprint":false},{"pmid":"30785094","id":"PMC_30785094","title":"LRP1 receptor-mediated immunosuppression of α-MMC on monocytes.","date":"2019","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30785094","citation_count":18,"is_preprint":false},{"pmid":"32896641","id":"PMC_32896641","title":"The Pseudomonas aeruginosa HSP90-like protein HtpG regulates IL-8 expression through NF-κB/p38 MAPK and CYLD signaling triggered by TLR4 and CD91.","date":"2020","source":"Microbes and infection","url":"https://pubmed.ncbi.nlm.nih.gov/32896641","citation_count":18,"is_preprint":false},{"pmid":"37310025","id":"PMC_37310025","title":"Jun-APOE-LRP1 axis promotes tumor metastasis in colorectal cancer.","date":"2023","source":"Biomolecules & biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/37310025","citation_count":17,"is_preprint":false},{"pmid":"40301361","id":"PMC_40301361","title":"Genome-wide CRISPR screening identifies LRP1 as an entry factor for SFTSV.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40301361","citation_count":16,"is_preprint":false},{"pmid":"12402342","id":"PMC_12402342","title":"The LDL receptor-related protein (LRP1/A2MR) and coronary atherosclerosis--novel genomic variants and functional consequences.","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12402342","citation_count":16,"is_preprint":false},{"pmid":"40484331","id":"PMC_40484331","title":"LRP1 at the crossroads of Parkinson's and Alzheimer's: Divergent roles in α-synuclein and amyloid pathology.","date":"2025","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40484331","citation_count":16,"is_preprint":false},{"pmid":"34441867","id":"PMC_34441867","title":"Apolipoprotein and LRP1-Based Peptides as New Therapeutic Tools in Atherosclerosis.","date":"2021","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34441867","citation_count":16,"is_preprint":false},{"pmid":"35588160","id":"PMC_35588160","title":"Guiding Epilepsy Surgery with an LRP1-Targeted SPECT/SERRS Dual-Mode Imaging Probe.","date":"2022","source":"ACS applied materials & interfaces","url":"https://pubmed.ncbi.nlm.nih.gov/35588160","citation_count":16,"is_preprint":false},{"pmid":"30523204","id":"PMC_30523204","title":"Hemin induces autophagy in a leukemic erythroblast cell line through the LRP1 receptor.","date":"2019","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/30523204","citation_count":16,"is_preprint":false},{"pmid":"37179044","id":"PMC_37179044","title":"Andrographolide exerts a neuroprotective effect by regulating the LRP1-mediated PPARγ/NF-κB pathway.","date":"2023","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37179044","citation_count":15,"is_preprint":false},{"pmid":"8273915","id":"PMC_8273915","title":"Mapping of MYF5, C1R, MYHL, TPI1, IAPP, A2MR and RNR onto sheep chromosome 3q.","date":"1993","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8273915","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47782,"output_tokens":13145,"usd":0.170261,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":24976,"output_tokens":8167,"usd":0.164527,"stage2_stop_reason":"end_turn"},"total_usd":0.334788,"stage1_batch_id":"msgbatch_0147LFpL5iCPFZF66xp23BqC","stage2_batch_id":"msgbatch_01Crtwc6eCsZh1CrnfJhY7J7","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"CD91 (LRP1) was identified as a direct cell-surface receptor for heat shock protein gp96 on antigen-presenting cells. CD91 binds gp96 directly (not through another intermediate ligand), and the known CD91 ligand alpha-2-macroglobulin competitively inhibits gp96-chaperoned peptide re-presentation by macrophages. Anti-CD91 antibodies also block re-presentation, establishing CD91 as the receptor mediating gp96-peptide uptake and MHC class I cross-presentation.\",\n      \"method\": \"Direct binding assay, competitive inhibition with alpha-2-macroglobulin, antibody blockade of re-presentation in macrophages\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding evidence, competitive inhibition with known ligand, antibody blockade, replicated across multiple subsequent studies\",\n      \"pmids\": [\"11248808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CD91 (LRP1) serves as a common receptor for multiple heat shock proteins — gp96, hsp90, hsp70, and calreticulin — on macrophages and dendritic cells. All of these HSPs use CD91 to mediate uptake and MHC class I re-presentation of chaperoned peptides. Post-uptake processing requires proteasomes and TAP transporters, utilizing the classical endogenous antigen presentation pathway.\",\n      \"method\": \"Uptake assays with multiple HSPs in macrophages and dendritic cells; MHC class I re-presentation assays; inhibitor studies (proteasome inhibitors, TAP-deficient cells)\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple HSP ligands tested, pathway dissection with proteasome/TAP inhibitors, independently replicates CD91-gp96 finding and extends it\",\n      \"pmids\": [\"11290339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Alpha-2-macroglobulin (alpha-2M) binds peptides in vitro and, as a CD91 (LRP1) ligand, can chaperone peptides for re-presentation by CD91+ APCs on MHC class I molecules, priming peptide-specific CD8+ T cell responses. This demonstrates alpha-2M functions similarly to gp96 as a T cell adjuvant through CD91.\",\n      \"method\": \"In vitro peptide binding assay; immunization of mice with alpha-2M-peptide complexes; re-presentation assays in CD91+ APCs\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro binding plus in vivo immunization, single lab\",\n      \"pmids\": [\"11290775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CD91 (LRP1) is essential for re-presentation of gp96-chaperoned peptides by antigen-presenting cells. siRNA-mediated knockdown of CD91 in APCs caused a corresponding and dramatic decline in re-presenting ability; recovery of CD91 expression restored re-presentation ability. Anti-CD91 antisera abrogated protective tumor immunity elicited by tumor-derived gp96-peptide complexes in vivo.\",\n      \"method\": \"siRNA knockdown of CD91; in vitro re-presentation assays; in vivo tumor immunity assays with anti-CD91 antisera\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — siRNA loss-of-function with recovery, in vitro and in vivo validation, multiple orthogonal readouts\",\n      \"pmids\": [\"15073331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"LRP1 associates with and is functionally required for the endocytosis of neuronal prion protein (PrPC). LRP1 inhibition by siRNA reduces surface PrPC and causes its accumulation in biosynthetic compartments, indicating LRP1 expedites PrPC trafficking to the neuronal surface. PrPC and LRP1 co-immunoprecipitate from the endoplasmic reticulum, and the N-terminal domain of PrPC binds purified human LRP1 with nanomolar affinity even in the presence of the LRP1 chaperone RAP.\",\n      \"method\": \"siRNA knockdown, co-immunoprecipitation, in vitro binding assay (nanomolar affinity measurement), surface PrPC quantification\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro binding with affinity measurement, co-IP from ER, siRNA functional validation, multiple orthogonal methods in single study\",\n      \"pmids\": [\"18285446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LRP1 is shed from macrophages by ADAM17 in response to LPS and IFN-γ, generating soluble LRP1 (sLRP1). Both sLRP1 (from human plasma) and full-length LRP1 (from mouse liver) activate cell signaling (p38 MAPK, JNK, IKK-NF-κB) when added to macrophage cultures and induce expression of TNF-α, MCP-1/CCL2, and IL-10. Ligand-binding cluster-directed proteins fail to inhibit sLRP1 signaling, but an antibody targeting the sLRP1 N-terminus is effective.\",\n      \"method\": \"ADAM17 inhibition studies; purified sLRP1 and full-length LRP1 added to RAW 264.7 cells and BMMs; western blot for signaling kinases; cytokine measurement; blocking antibody experiments; in vivo LPS model\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — purified protein added to cells, in vivo confirmation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"20610799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CD91 (LRP1) directly binds C1q. Surface plasmon resonance and ELISA demonstrate a direct, saturable, time-dependent interaction between purified C1q and purified CD91 that is inhibited by known ligands of both proteins. CD91 expression on monocytes correlates with C1q binding, and the CD91 chaperone RAP inhibits this binding.\",\n      \"method\": \"ELISA, surface plasmon resonance (SPR), flow cytometry of monocytes, RAP inhibition assay\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — SPR and ELISA with purified proteins, specificity controls (competitive inhibition), single lab\",\n      \"pmids\": [\"20716178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LRP1 regulates Notch3 signaling through thrombospondin-2 (TSP2). TSP2 potentiation of Notch3 is blocked by RAP (LRP inhibitor) and requires LRP1 expression in the signal-sending cell. TSP2 stimulates Notch3 endocytosis into wild-type but not LRP1-deficient fibroblasts. Recombinant Notch3 and Jagged1 interact with the LRP1 85-kDa B-chain (a subunit lacking known ligand-binding function), suggesting LRP1 and TSP2 stimulate Notch activity by driving trans-endocytosis of the Notch ectodomain.\",\n      \"method\": \"RAP inhibition, LRP1-deficient fibroblast comparisons, Notch3 endocytosis assay, recombinant protein interaction assay with LRP1 B-chain\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — LRP1-deficient cells compared to WT, RAP inhibition, protein interaction assay, single lab\",\n      \"pmids\": [\"20472562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LRP1 directly binds leptin and the leptin receptor complex and is required for leptin receptor phosphorylation and Stat3 activation. Conditional deletion of Lrp1 in the brain resulted in an obese phenotype (increased food intake, decreased energy consumption, decreased leptin signaling). Hypothalamus-specific deletion via Cre lentivirus was sufficient to trigger accelerated weight gain.\",\n      \"method\": \"Conditional brain-specific and hypothalamus-specific Lrp1 knockout mice; direct binding assay (LRP1 binds leptin and leptin receptor complex); leptin receptor phosphorylation and Stat3 activation assays\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with specific phenotypic readout, direct binding demonstration, regional specificity confirmed by Cre lentivirus injection, multiple orthogonal approaches\",\n      \"pmids\": [\"21264353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LRP1 regulates the cell-surface abundance of urokinase receptor (uPAR) by facilitating its endocytosis, thereby controlling uPAR-initiated cell signaling including ERK, PI3K, and Rac1 pathways. In some cell types LRP1 directly activates cell-signaling upon ligand binding, and it also indirectly regulates signaling by modulating the plasma membrane proteome (e.g., uPAR levels).\",\n      \"method\": \"Review synthesizing LRP1 endocytosis and signaling studies; cell-based uPAR endocytosis and signaling assays described\",\n      \"journal\": \"Current pharmaceutical design\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — review paper summarizing prior experimental work without new primary data presented\",\n      \"pmids\": [\"21711236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"LRP1 is the receptor mediating H. pylori VacA toxin-induced autophagy in gastric epithelial cells. VacA binds LRP1 and its internalization through LRP1 regulates LC3-II generation (autophagosome formation) and subsequent apoptosis (PARP cleavage). Knockdown of LRP1 inhibited both VacA-induced autophagy and apoptosis. Other VacA receptors (RPTPα, RPTPβ, fibronectin) did not mediate autophagy.\",\n      \"method\": \"LRP1 knockdown (siRNA), LC3-II western blot, PARP cleavage assay, comparison with other VacA receptor knockdowns\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific receptor identification by knockdown with multiple functional readouts, negative controls (other receptors), single lab\",\n      \"pmids\": [\"22822085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CD91 (LRP1) functions as a signaling receptor for HSPs (gp96, hsp70, calreticulin) on APCs, triggering phosphorylation of CD91 and activation of NF-κB signaling cascades leading to APC maturation, cytokine secretion, and priming of T-helper cell subsets. Each HSP-CD91 interaction stimulates a unique cytokine profile dictating specific Th cell subset priming.\",\n      \"method\": \"CD91 phosphorylation assays, NF-κB activation assays, cytokine profiling, Th cell priming experiments, CD91-dependent signaling in APCs\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphorylation and NF-κB activation assays, CD91-dependent Th cell priming, multiple HSPs tested with distinct cytokine profiles\",\n      \"pmids\": [\"22045000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LRP1 deletion in Schwann cells causes abnormalities in axon myelination and ensheathment of axons in Remak bundles, resulting in mechanical allodynia even without nerve injury. After crush injury, sciatic nerves in scLRP1−/− mice showed accelerated degeneration, Schwann cell death, and failure to remyelinate. LRP1 is identified as an essential mediator of Schwann cell-axon interactions and the Schwann cell response to PNS injury.\",\n      \"method\": \"Conditional Schwann cell-specific LRP1 knockout (scLRP1−/−), behavioral pain assays, nerve crush model, histological analysis of myelination and Remak bundles, spinal cord microglial activation assays\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type specific conditional KO, multiple phenotypic readouts (anatomy, behavior, central sensitization), specific injury models\",\n      \"pmids\": [\"23536074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Myeloid cell LRP1 regulates macrophage migration and chemokine expression via NF-κB. LRP1 deletion in myeloid cells increased monocyte recruitment to tumors, elevated CCL3/MIP-1α expression in macrophages, and increased tumor angiogenesis. LRP1-deficient macrophages migrated faster than LRP1-expressing cells, an effect reversed by CCL3-neutralizing antibody, CCR5-neutralizing antibody, or NF-κB inhibition.\",\n      \"method\": \"Myeloid-specific LRP1 knockout mice, orthotopic tumor model, chemokine expression analysis, in vitro migration assay, neutralizing antibodies, NF-κB inhibitor\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — myeloid-specific KO with in vivo tumor model, mechanistic rescue experiments, multiple orthogonal approaches\",\n      \"pmids\": [\"23633492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"LRP1 is required for the constitutive endocytosis and lysosomal degradation of cell-surface transglutaminase. Transglutaminase interacts with LRP1 in vitro and on the cell surface (co-immunoprecipitation). LRP1 deficiency or blockade of endo-lysosomal function upregulates transglutaminase surface expression, leading to increased cell adhesion and matrix crosslinking. Fibronectin and PDGF promote transglutaminase endocytosis via LRP1.\",\n      \"method\": \"In vitro binding assay, co-immunoprecipitation, LRP1 deficiency model, surface expression assays, adhesion assays, ligand-stimulated endocytosis\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, in vitro binding, LRP1-deficient cell comparisons, multiple functional readouts in single study\",\n      \"pmids\": [\"17711877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LRP1 regulates reverse cholesterol transport by controlling cPLA2 phosphorylation and ABCA1 expression. Absence of LRP1 increases PDGFRβ signaling, activating MAPK which phosphorylates cPLA2, releasing arachidonic acid that suppresses LXR/RXR-mediated ABCA1 transcription, reducing cholesterol efflux. LRP1 thus functions as a physiological integrator of cellular lipid homeostasis.\",\n      \"method\": \"LRP1-deficient cells, PDGFRβ signaling assays, cPLA2 phosphorylation assays, arachidonic acid measurement, LXR/RXR promoter assays, ABCA1 expression analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — LRP1-deficient cell system, sequential pathway validation, single lab with multiple biochemical readouts\",\n      \"pmids\": [\"19718435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LRP1 controls adipogenesis and lipid homeostasis in adipocytes. LRP1 silencing in preadipocytes inhibits expression of PPARγ, HSL, and aP2 adipocyte differentiation markers and results in lipid-depleted cells. In fully differentiated adipocytes, LRP1 silencing reduces cellular lipid levels and is associated with increased basal lipolysis.\",\n      \"method\": \"siRNA knockdown of LRP1 in 3T3F442A preadipocytes and differentiated adipocytes, adipocyte differentiation marker expression, lipid staining, lipolysis assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with specific differentiation and lipid accumulation readouts, single lab\",\n      \"pmids\": [\"19823686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LRP1 modulates sphingosine-1-phosphate (S1P) signaling and is essential for vascular development. Loss of LRP1 leads to lethal vascular defects with failure of mural cell investment of vessels. LRP1 integrates S1P and PDGF-BB signaling pathways via its intracellular domain; loss of LRP1 prevents S1P-dependent inhibition of RAC1 and removes constraint on PDGF-BB-induced cell migration.\",\n      \"method\": \"Genetically engineered mouse models, S1P signaling assays, RAC1 activity measurement, PDGF-BB migration assays, intracellular domain analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO with lethal vascular phenotype, mechanistic dissection of S1P/PDGF pathway integration via LRP1 intracellular domain\",\n      \"pmids\": [\"25377550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRP1 (along with LDL receptor) mediates mannose 6-phosphate-independent lysosomal targeting of cathepsins D and B. LRP1-deficient fibroblasts fail to internalize non-phosphorylated cathepsins B and D, and LRP1 inhibitor increases secretion of cathepsin D from M6P-deficient cells. LRP1 thus functions in a secretion-recapture targeting mechanism for lysosomal enzymes.\",\n      \"method\": \"SILAC-based comparative mass spectrometry of lysosomal proteome, fibroblasts deficient for LRP1 or LDLR, LRP1 inhibitor treatment, cathepsin secretion assays\",\n      \"journal\": \"Traffic (Copenhagen, Denmark)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor-deficient cell lines, proteomics, functional secretion assays, single lab\",\n      \"pmids\": [\"25786328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRP1 interacts with PARP-1 in human retinal microvascular endothelial cells, and this interaction decreases under hypoxia. LRP1 knockdown results in increased PARP-1 activity and subsequent phosphorylation of retinoblastoma protein and CDK2, promoting cell cycle progression. Endothelial LRP1 deletion increases retinal neovascularization in oxygen-induced retinopathy.\",\n      \"method\": \"Co-immunoprecipitation (LRP1-PARP-1 interaction), LRP1 endothelial knockout mice, oxygen-induced retinopathy model, Ki67 staining, PARP-1 activity assay, Rb and CDK2 phosphorylation assays\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP identifying novel LRP1-PARP-1 interaction, endothelial KO mouse with in vivo angiogenesis phenotype, downstream signaling cascade validated\",\n      \"pmids\": [\"26634655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LRP1 microglia expression is protective during CNS autoimmunity (EAE). LRP1 functions as an inhibitor of NF-κB activation in myeloid cells via a MyD88-dependent pathway. Deletion of LRP1 in microglia (but not peripheral macrophages) increases EAE severity and causes microglia to adopt a pro-inflammatory phenotype with amoeboid morphology and increased TNF-α production.\",\n      \"method\": \"Microglia-specific and peripheral macrophage-specific LRP1 knockout mice, EAE model, NF-κB activation assays, cytokine measurement (TNF-α), morphological analysis\",\n      \"journal\": \"Acta neuropathologica communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type specific conditional KO (microglia vs macrophage), MyD88-dependent NF-κB pathway identification, specific in vivo disease model\",\n      \"pmids\": [\"27400748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The intracellular domain of LRP1 interacts with the nuclear receptor PPARγ and acts as its transcriptional co-activator in endothelial cells. Endothelial-specific Lrp1 deletion in mice improves glucose sensitivity and lipid profiles with increased oxygen consumption under high-fat diet conditions.\",\n      \"method\": \"Endothelial-specific LRP1 knockout mice, co-immunoprecipitation (LRP1 ICD with PPARγ), transcriptional co-activation assays, metabolic phenotyping\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP demonstrating LRP1 ICD-PPARγ interaction, endothelial-specific KO with metabolic phenotype, single lab with orthogonal methods\",\n      \"pmids\": [\"28393867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TLR activation leads to phosphorylation of LRP1 at Y4507 in macrophages, which recruits the GTPase Rab8a and its PI3Kγ effector complex (p110γ/p101) to macropinosomal membranes. CRISPR KO of LRP1 abolishes TLR-induced Rab8a activation and alters Akt/mTOR signaling, producing a pro-inflammatory cytokine bias. This TLR-LRP1-Rab8a/PI3Kγ axis reprograms macrophages to suppress inflammation.\",\n      \"method\": \"CRISPR knockout of LRP1, LRP1 phosphorylation at Y4507 assay, Rab8a activation assay, Co-IP/recruitment assays, cytokine profiling, confocal microscopy\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO, specific phosphorylation site identified, Rab8a recruitment assay, comparison with Rab8a-KO and PI3Kγ-null phenotypes, multiple methods\",\n      \"pmids\": [\"30208326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"p53 regulates LRP1 expression as a direct target gene. LRP1 transcript is upregulated by both sub-lethal and lethal p53-activating stress, but LRP1 protein is only elevated under sub-lethal stress. Lethal stress induces p53-regulated miRNAs (miR-103 and miR-107) that suppress LRP1 translation, resulting in reduced LRP1 protein and cell death. This constitutes a negative feedback loop.\",\n      \"method\": \"p53 target gene identification, miRNA overexpression, LRP1 transcript and protein measurement under different stress levels, miR-103/107 functional assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct p53 target identification, miRNA-based translational repression demonstrated with functional consequences, single lab\",\n      \"pmids\": [\"30089260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"APOE4-mediated amyloid-β (Aβ) pathology depends on neuronal LRP1. Neuronal LRP1 deficiency in APP/PS1/APOE4 mice reversed APOE4-dependent increases in Aβ deposition and insoluble Aβ40/Aβ42. LRP1 deficiency increased detergent-soluble apoE4 levels, which may contribute to inhibition of Aβ deposition. The data establish that apoE4 exacerbates Aβ pathology through a mechanism requiring neuronal LRP1.\",\n      \"method\": \"Neuronal LRP1 conditional knockout crossed with APP/PS1 and APOE3/4 targeted replacement mice, amyloid plaque quantification, Aβ ELISA, apoE level measurement\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — triple-cross genetic model, APOE3 vs APOE4 comparison, multiple Aβ readouts, APOE genotype-dependent mechanism\",\n      \"pmids\": [\"30741718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Extracellular HSP90α and clusterin synergistically promote breast cancer EMT and metastasis via LRP1. Clusterin participates in eHsp90α-LRP1 complex formation (demonstrated by proximity ligation assay and co-IP) and enhances eHsp90α binding affinity to LRP1, potentiating AKT, ERK, and NF-κB activation and EMT.\",\n      \"method\": \"Proximity ligation assay, co-immunoprecipitation, in vitro cell migration/invasion assays, in vivo metastasis model, AKT/ERK/NF-κB activation assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — PLA and co-IP demonstrating trimeric complex, LRP1 as mediator with in vivo validation, single lab\",\n      \"pmids\": [\"31273033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LRP1 controls the endocytosis of tau and its subsequent neuronal spread. LRP1 knockdown significantly reduced tau uptake in H4 neuroglioma cells and iPSC-derived neurons. The interaction between tau and LRP1 is mediated by lysine residues in the microtubule-binding repeat region of tau. Downregulation of LRP1 in a mouse model of tau spread effectively reduced tau propagation between neurons.\",\n      \"method\": \"LRP1 knockdown (siRNA), iPSC-derived neurons, fluorescence-based tau uptake assay, in vivo mouse tau spread model (AAV-mediated), lysine residue mapping\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple cell systems, in vivo mouse model, specific interaction domain mapping (lysine residues), replicated across cell types and in vivo\",\n      \"pmids\": [\"32296178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LRP1 mutation in cardiac neural crest cells (CNCs) causes congenital heart defects by perturbing outflow tract lengthening. Lrp1 missense mutant (C4232R) and CNC-specific conditional deletion both reproduce atrioventricular septal defects and double outlet right ventricle. Mutant LRP1 is retained in the ER, reducing LRP1 surface expression and impairing cell motility and focal adhesion turnover. Loss of LRP1 in CNCs perturbs Wnt and other signaling pathways.\",\n      \"method\": \"Knock-in mouse model (C4232R missense), CNC-specific conditional Lrp1 deletion, outflow tract morphometry, cushion explant migration assay, gene expression analysis, ER retention assay, focal adhesion turnover assay\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in and conditional KO models recapitulate phenotype, ER retention mechanism established, cell motility and signaling mechanistically linked\",\n      \"pmids\": [\"32546759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RVFV glycoprotein (Gn) directly binds to specific Lrp1 clusters in a glycosylation-independent manner, establishing Lrp1 as a host entry factor for Rift Valley fever virus. Murine RAP domain 3 (mRAPD3) and anti-Lrp1 antibodies neutralize RVFV infection in diverse cell lines, and mRAPD3 treatment protects mice from lethal RVFV. A mutant mRAPD3 with weak Lrp1 binding failed to protect.\",\n      \"method\": \"Genome-wide CRISPR screen, direct binding assay (Gn to Lrp1 clusters), neutralization assays with RAP domain 3 and anti-Lrp1 antibodies, in vivo mouse protection study with mRAPD3\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — CRISPR screen identification, direct binding assay, multiple neutralization approaches, in vivo protection with structure-function (mutant mRAPD3), genome-wide validation\",\n      \"pmids\": [\"34559985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Endothelial LRP1 protects against neurodegeneration by blocking the cyclophilin A-MMP-9 pathway. LRP1 inactivation from mouse endothelium causes a self-autonomous activation of cyclophilin A-MMP-9 in endothelium, leading to loss of tight junctions and blood-brain barrier breakdown, followed by neuron loss and cognitive deficits. Cyclophilin A inhibition in endothelial LRP1-KO mice restored BBB integrity and reversed neuronal loss. Endothelial-specific LRP1 gene therapy reversed the phenotype.\",\n      \"method\": \"Endothelial-specific LRP1 knockout mice, cyclophilin A-MMP-9 pathway assays, tight junction protein quantification, BBB integrity assays, behavioral tests, gene therapy rescue, cyclophilin A inhibitor treatment\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — endothelial-specific KO, pathway inhibitor rescue, gene therapy rescue, multiple readouts (BBB, neurons, behavior), two independent rescue strategies\",\n      \"pmids\": [\"33533918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Brain endothelial LRP1 ablation causes protease-mediated tight junction degradation, P-glycoprotein reduction, and loss of blood-brain barrier integrity, confirming LRP1's role in maintaining BBB structural integrity in CNS endothelium specifically.\",\n      \"method\": \"CNS endothelial-specific conditional Lrp1 knockout (Slco1c1-CreERT2), tight junction protein analysis, P-gp measurement, BBB permeability assays\",\n      \"journal\": \"Fluids and barriers of the CNS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CNS-specific conditional KO, multiple BBB readouts, single lab replicating and extending prior findings\",\n      \"pmids\": [\"34147102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LRP1 is a neuronal receptor for α-synuclein uptake and spread. LRP1 knockout in human iPSC-derived neurons significantly reduced uptake of monomeric and oligomeric α-Syn, and to a lesser extent PFF uptake. Blocking lysine residues on α-Syn decreased its LRP1-mediated uptake, and the N-terminus of α-Syn was critical for LRP1-mediated internalization. Neuronal Lrp1 conditional KO in mice significantly reduced α-Syn spread in the brain.\",\n      \"method\": \"CRISPR/Cas9 LRP1-KO iPSC-derived neurons, flow cytometry uptake assay, lysine capping with sulfo-NHS acetate, N-terminus deletion, neuronal Lrp1 conditional KO mouse model with AAV-based spread assay\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO in human neurons, multiple α-Syn species tested, specific domain mapping (lysine, N-terminus), in vivo spread model in conditional KO mice\",\n      \"pmids\": [\"36056345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"OROV (Oropouche orthobunyavirus) uses LRP1 for efficient cellular entry. VSV expressing OROV glycoproteins bound to the LRP1 ectodomain in vitro. RAP treatment and recombinant LRP1 ectodomain truncations reduced OROV infection. RAP treatment of mice reduced tissue viral load and improved survival from lethal infection.\",\n      \"method\": \"Lrp1-deficient cells (multiple species), in vitro binding assay (VSV-OROV to LRP1 ectodomain), RAP inhibition, recombinant LRP1 ectodomain competition, in vivo mouse protection study\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct binding assay, multiple cell line systems, in vivo protection, mechanistic connection to RVFV entry via same receptor\",\n      \"pmids\": [\"35939689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Extracellular HMGB1 impairs macrophage-mediated efferocytosis by suppressing Rab43, which is required for anterograde transport of CD91 (LRP1) from the cytoplasm to the cell surface. Rab43 directly interacts with CD91 to mediate its intracellular trafficking. Rab43 KO delays inflammation resolution and aggravates lung damage in ALI mice.\",\n      \"method\": \"BMDM efferocytosis assay, Rab43 knockdown/KO, CD91 surface transport assay, co-immunoprecipitation (Rab43-CD91), confocal microscopy, in vivo ALI mouse model\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP identifying Rab43-CD91 interaction, Rab43 KO with CD91 trafficking defect, in vivo validation, single lab\",\n      \"pmids\": [\"35392093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ANKS1A associates with the NPXY motifs of LRP1 and facilitates transport of LRP1 from the endoplasmic reticulum to the cell surface. Endothelial ANKS1A deficiency reduces cell surface LRP1 levels and impairs Aβ clearance across the BBB. In an AD mouse model, ANKS1A deficiency exacerbates Aβ pathology and cognitive impairment, reversible by endothelial-specific ANKS1A gene therapy.\",\n      \"method\": \"Co-immunoprecipitation (ANKS1A-LRP1 NPXY motifs), endothelial ANKS1A KO mice, surface LRP1 quantification, Aβ clearance assay, iPSC-derived BBB with ANKS1A KO or rs6930932 variant, AD mouse model gene therapy rescue\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — co-IP with specific domain (NPXY), KO with surface trafficking defect, in vivo AD model, human iPSC-derived BBB validation, gene therapy rescue\",\n      \"pmids\": [\"38123547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"LRP1 is identified as an entry factor for SFTS virus. SFTSV glycoprotein Gn interacts with LRP1 CLI and CLII domains (demonstrated by co-IP and surface plasmon resonance). LRP1 knockdown/knockout attenuates SFTSV infection. LRP1 antagonists and neutralizing antibodies reduce SFTSV infection, and LRP1-neutralizing antibody treatment in mice reduces viral load and improves survival.\",\n      \"method\": \"Genome-wide CRISPR knockout screen, co-immunoprecipitation, surface plasmon resonance (SPR), siRNA knockdown, neutralizing antibody treatment in cells and mice\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — CRISPR screen, SPR direct binding assay with domain specificity, in vivo mouse protection, multiple validation approaches\",\n      \"pmids\": [\"40301361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Astrocytic LRP1 promotes astrocyte-to-neuron mitochondria transfer by suppressing glucose uptake, glycolysis, and lactate production, thereby reducing ARF1 lactylation. Suppression of astrocytic LRP1 reduced mitochondria transfer into damaged neurons and worsened ischemia-reperfusion injury. This identifies LRP1 as a regulator of lactate-ARF1 lactylation signaling in astrocytes.\",\n      \"method\": \"Astrocyte-specific LRP1 manipulation, glycolysis/lactate production measurement, ARF1 lactylation assays, mitochondria transfer assays, mouse ischemia-reperfusion model, CSF lactate measurement in human stroke patients\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic pathway (LRP1→glycolysis→lactate→ARF1 lactylation→mitochondria transfer) established in cells and in vivo, human patient correlation\",\n      \"pmids\": [\"38906140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PCSK9 promotes breast cancer metastasis by targeting tumoral LRP1 receptors, which represses metastasis-suppressing genes XAF1 and USP18. Host PCSK9 enhances metastatic proliferative competence in the lung via LRP1. Antibody-mediated therapeutic inhibition of PCSK9 suppresses breast cancer metastasis in multiple models.\",\n      \"method\": \"Genetic modeling of PCSK9 gain-of-function SNV in mice, host PCSK9 deletion models, LRP1 receptor identification as PCSK9 target, XAF1/USP18 gene expression analysis, anti-PCSK9 antibody treatment models\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple mouse models, LRP1 identified as downstream target with gene expression readout, single lab\",\n      \"pmids\": [\"39657676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The VWF-A1 domain binds to LRP1 clusters II and IV via a conserved cluster of lysine residues (K1405-K1408). Alanine mutagenesis of this cluster significantly attenuated VWF binding to both LRP1 clusters II and IV, reduced intracellular degradation, and prolonged VWF in vivo clearance. The aptamer BT200 blocks this K1405-K1408/LRP1 interaction, attenuating macrophage-mediated VWF clearance.\",\n      \"method\": \"Alanine mutagenesis of VWF-K1405-K1408, ELISA and SPR binding to LRP1 clusters II and IV, in vivo VWF clearance experiments, BT200 aptamer competition assay, HEK-LRP1 cell binding assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with direct binding assay (SPR/ELISA), in vivo clearance validation, specific LRP1 cluster mapping, aptamer competition confirms site specificity\",\n      \"pmids\": [\"38996211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"LRP1 is phosphorylated on both serine and tyrosine residues; tyrosine-phosphorylated LRP1 specifically associates with the cellular docking protein Shc, implicating LRP1 in signal transduction and suggesting that ligand internalization is regulated by phosphorylation.\",\n      \"method\": \"Phosphorylation assays, co-immunoprecipitation of phospho-LRP1 with Shc\",\n      \"journal\": \"Trends in cardiovascular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — review summarizing prior findings on LRP1 phosphorylation and Shc association without new primary data\",\n      \"pmids\": [\"12069755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LRP1 activities (endocytosis and cell-signaling) compartmentalize into distinct plasma membrane microdomains. In neuron-like cells, LRP1 distributes into lipid rafts and non-raft fractions; disruption of lipid rafts blocks LRP1-mediated Src family kinase and ERK1/2 activation and neurite outgrowth/cell growth, without affecting total ligand binding capacity or endocytic activity of LRP1.\",\n      \"method\": \"Lipid raft fractionation, methyl-β-cyclodextrin and fumonisin B1 treatment, ERK1/2 and Src kinase activation assays, neurite outgrowth assays, LRP1 ligand binding and endocytosis assays in PC12, N2a, and cerebellar granule neurons\",\n      \"journal\": \"Molecular and cellular neurosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — lipid raft disruption with two independent reagents, multiple cell types including primary neurons, orthogonal functional readouts, single lab\",\n      \"pmids\": [\"27565578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LRP1 promotes infection by multiple RNA viruses (RVFV, sandfly fever Sicilian virus, La Crosse virus, and SARS-CoV-2) by acting at attachment and entry stages. LRP1 inactivation in human cells reduced RVFV RNA levels at entry. LRP1's role in RVFV infection depends on physiological levels of cholesterol and on endocytosis.\",\n      \"method\": \"Haploid insertion-mutagenesis screen, LRP1 inactivation in human cells, RVFV RNA level measurement at entry, siRNA experiments for SARS-CoV-2 in Calu-3 cells, cholesterol and endocytosis inhibitor experiments\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple virus species tested, entry-stage identification, cholesterol/endocytosis dependence established, single lab\",\n      \"pmids\": [\"37072184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Lrp1 is essential for RVFV hepatic disease in mice. Hepatocyte-specific Lrp1 deletion results in minimal RVFV replication in the liver, longer time to death, and shift toward neurological disease. RVFV infection levels in non-hepatic tissues were unaffected, establishing that Lrp1 in hepatocytes specifically mediates viral hepatic tropism.\",\n      \"method\": \"Hepatocyte-specific Lrp1 conditional KO mice, RVFV infection, liver viral replication quantification, survival analysis, tissue-specific viral load comparison\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — hepatocyte-specific conditional KO, tissue-specific viral load comparison, demonstrates organ-specific LRP1 role in disease\",\n      \"pmids\": [\"37450601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LRP1 mediates midkine (MK) endocytosis in chondrocytes and acts as a translocator delivering MK intracellularly where it forms a complex with nucleolin that interacts with active K-Ras, leading to ERK1/2 activation and cyclin D1 upregulation to promote chondrocyte proliferation.\",\n      \"method\": \"shRNA knockdown of LRP1, co-immunoprecipitation (MK-nucleolin-K-Ras complex), Western blot for ERK1/2 and cyclin D1, CCK8 proliferation assay, flow cytometry\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP identifying intracellular complex, siRNA functional validation, downstream signaling cascade demonstrated, single lab\",\n      \"pmids\": [\"31639491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LRP1 heterozygous deficiency causes developmental dysplasia of the hip (DDH) by impairing triradiate chondrocyte differentiation through inhibition of autophagy with β-catenin upregulation. Lrp1 deficiency in mice accelerates triradiate cartilage development timing and reduces chondrogenic ability. Loss of LRP1 decreases autophagy with significant β-catenin upregulation; chondrocyte marker expression is rescued by β-catenin antagonist PNU-74654.\",\n      \"method\": \"Heterozygous Lrp1 KO mice, Lrp1 knock-in mice (DDH missense variant), in vitro chondrogenesis assay, autophagy measurement, β-catenin assay, PNU-74654 rescue experiment, shRNA in ATDC5 cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO and knock-in models, mechanistic rescue with β-catenin antagonist, in vitro chondrogenesis validation, single lab\",\n      \"pmids\": [\"36067312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Celastrol directly binds the LRP1 β-chain and abolishes LRP1 interaction with the transcription factor c-Jun in the nucleus, thereby inhibiting CCL2 production by skin fibroblasts, blocking fibroblast-macrophage crosstalk, and ameliorating psoriasis. Fibroblast-specific LRP1 KO mice showed significant reduction in psoriasis-like inflammation.\",\n      \"method\": \"Direct binding assay (celastrol to LRP1 β-chain), co-IP (LRP1 β-chain with c-Jun), fibroblast-specific LRP1 KO mice, psoriasis murine and cynomolgus monkey models, CCL2 measurement\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding and co-IP identifying nuclear LRP1-c-Jun interaction, fibroblast-specific KO phenotype, in vivo psoriasis models, single lab\",\n      \"pmids\": [\"40177548\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LRP1 (CD91) is a large multifunctional endocytic and signaling transmembrane receptor that mediates uptake of diverse extracellular ligands (heat shock proteins, ApoE, tau, α-synuclein, prion protein, VWF, transglutaminase, lysosomal enzymes, viral glycoproteins) via clathrin-coated pits in a lipid raft-compartmentalized manner, while simultaneously acting as a cell-signaling hub through ligand-induced and TLR crosstalk-induced phosphorylation (e.g., Y4507) that activates Rab8a/PI3Kγ, NF-κB, MAPK, and Src/ERK pathways; its intracellular domain directly interacts with PPARγ as a transcriptional co-activator, with PARP-1 to regulate cell proliferation, and with c-Jun to modulate gene expression; tissue-specific functions include BBB maintenance by blocking the cyclophilin A-MMP-9 pathway in endothelium, regulation of leptin-receptor signaling and energy homeostasis in the hypothalamus, Schwann cell-axon interactions in the PNS, tau and α-synuclein spread in neurons, and astrocyte-to-neuron mitochondria transfer via suppression of ARF1 lactylation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"LRP1 (CD91) is a large multifunctional endocytic and signaling transmembrane receptor that internalizes a structurally diverse repertoire of extracellular ligands and couples this uptake to intracellular signaling across immune, vascular, metabolic, and neuronal tissues [#0, #1, #11]. As an endocytic receptor it serves antigen-presenting cells by binding heat shock proteins (gp96, hsp90, hsp70, calreticulin) and alpha-2-macroglobulin to deliver chaperoned peptides into the MHC class I cross-presentation pathway, an activity essential for tumor immunity [#0, #1, #3]. The same receptor clears or traffics many additional cargoes \\u2014 prion protein, transglutaminase, M6P-independent cathepsins, von Willebrand factor, and the spreading neurodegenerative proteins tau and \\u03b1-synuclein, the latter two engaging LRP1 through lysine residues and N-terminal determinants to drive neuron-to-neuron propagation [#4, #14, #18, #38, #26, #31]. Beyond uptake, LRP1 functions as a signaling hub: ligand engagement and TLR crosstalk trigger phosphorylation (including at Y4507) that recruits Rab8a/PI3K\\u03b3 and modulates NF-\\u03baB, MAPK, and Akt/mTOR pathways to restrain inflammation in macrophages and microglia [#22, #20, #11], and these endocytic and signaling activities partition into distinct lipid-raft and non-raft membrane microdomains [#40]. Its intracellular domain integrates growth-factor and lipid signaling (PDGFR\\u03b2, S1P/RAC1, cPLA2/ABCA1) and acts directly in the nucleus as a transcriptional co-activator of PPAR\\u03b3 and as a partner of PARP-1 and c-Jun to control proliferation and gene expression [#17, #15, #21, #19, #45]. Tissue-specific genetic studies establish LRP1 as a controller of hypothalamic leptin signaling and energy balance, Schwann cell\\u2013axon interactions and remyelination, cardiac neural crest outflow-tract development, triradiate chondrocyte differentiation, and endothelial blood-brain barrier maintenance via suppression of the cyclophilin A\\u2013MMP-9 pathway [#8, #12, #27, #44, #29]. In neurodegeneration, neuronal LRP1 is required for APOE4-driven amyloid-\\u03b2 pathology, while its endothelial surface delivery by ANKS1A governs A\\u03b2 clearance across the BBB [#24, #34]. LRP1 is also a broadly exploited viral entry factor, with its ectodomain clusters directly bound by the glycoproteins of Rift Valley fever, Oropouche, and SFTS viruses to mediate attachment and tissue tropism [#28, #32, #35, #42].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established that CD91/LRP1 is the direct cell-surface receptor through which heat shock protein chaperones deliver peptides for MHC class I cross-presentation, defining LRP1's role in adaptive immunity.\",\n      \"evidence\": \"Direct binding, alpha-2-macroglobulin competitive inhibition, and antibody blockade of gp96 re-presentation in macrophages\",\n      \"pmids\": [\"11248808\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the structural binding interface on LRP1 for gp96\", \"Did not address whether other HSPs use the same receptor\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Generalized LRP1 as a common receptor for multiple HSPs and alpha-2-macroglobulin feeding into the proteasome/TAP-dependent presentation pathway, broadening its immunological scope.\",\n      \"evidence\": \"Uptake and re-presentation assays with gp96, hsp90, hsp70, calreticulin and alpha-2M; proteasome/TAP inhibitor and TAP-deficient cell studies\",\n      \"pmids\": [\"11290339\", \"11290775\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether distinct HSPs use overlapping or distinct LRP1 binding sites unresolved\", \"alpha-2M adjuvant function shown in a single lab\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrated LRP1 is functionally necessary, not merely correlative, for HSP-peptide presentation and tumor immunity, converting a binding observation into a causal requirement.\",\n      \"evidence\": \"siRNA knockdown with expression recovery and in vivo anti-CD91 antisera abrogating tumor immunity\",\n      \"pmids\": [\"15073331\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the intracellular routing of HSP-peptide complexes after LRP1 uptake\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed LRP1 mediates constitutive endocytosis and lysosomal degradation of cell-surface transglutaminase, extending its function to control of adhesion and matrix crosslinking.\",\n      \"evidence\": \"In vitro binding, co-IP, LRP1-deficient cells, surface expression and ligand-stimulated endocytosis assays\",\n      \"pmids\": [\"17711877\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding site on LRP1 not mapped\", \"Physiological context of transglutaminase regulation in vivo not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified LRP1 as required for prion protein trafficking and surface delivery, linking the receptor to neuronal protein handling with nanomolar binding affinity.\",\n      \"evidence\": \"siRNA knockdown, ER co-IP, in vitro binding affinity measurement, surface PrPC quantification\",\n      \"pmids\": [\"18285446\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish consequences for prion disease pathogenesis\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined LRP1 as a signaling receptor (not only endocytic), showing HSP-LRP1 engagement triggers receptor phosphorylation and NF-\\u03baB-driven APC maturation and Th-subset priming.\",\n      \"evidence\": \"CD91 phosphorylation and NF-\\u03baB assays, cytokine profiling, Th cell priming with multiple HSPs\",\n      \"pmids\": [\"22045000\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphorylation sites not mapped in this work\", \"Adaptors coupling phospho-LRP1 to NF-\\u03baB not identified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Connected LRP1 to systemic physiology by showing it binds leptin/leptin receptor and is required for hypothalamic leptin signaling and energy homeostasis.\",\n      \"evidence\": \"Brain- and hypothalamus-specific Lrp1 conditional KO, direct binding, leptin receptor phosphorylation and Stat3 activation assays\",\n      \"pmids\": [\"21264353\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism linking LRP1 to LepR phosphorylation not fully resolved\", \"Peripheral versus central contributions not dissected\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established cell-type-specific developmental and immune roles \\u2014 LRP1 in Schwann cells for myelination/repair and in myeloid cells for NF-\\u03baB-dependent migration and chemokine control.\",\n      \"evidence\": \"Schwann-cell-specific and myeloid-specific conditional KO with injury, behavior, tumor models, and neutralizing antibody/NF-\\u03baB inhibitor rescue\",\n      \"pmids\": [\"23536074\", \"23633492\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligands driving Schwann cell LRP1 signaling not defined\", \"Link between endocytic and NF-\\u03baB-regulatory functions unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Revealed that the LRP1 intracellular domain integrates S1P and PDGF-BB signaling to constrain RAC1-driven migration, explaining its essential role in vascular mural cell development.\",\n      \"evidence\": \"Genetically engineered mice with lethal vascular phenotype, S1P/RAC1/PDGF-BB signaling and migration assays, ICD analysis\",\n      \"pmids\": [\"25377550\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ICD-effector interactions not biochemically resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed LRP1 provides an M6P-independent secretion-recapture route for lysosomal enzyme targeting, broadening its endocytic substrate range to cathepsins.\",\n      \"evidence\": \"SILAC lysosomal proteomics, LRP1/LDLR-deficient fibroblasts, LRP1 inhibitor and cathepsin secretion assays\",\n      \"pmids\": [\"25786328\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; binding determinants on cathepsins not mapped\", \"Relative contribution versus LDLR not quantified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated a nuclear transcriptional function: the LRP1 ICD interacts with PPAR\\u03b3 as a co-activator, linking the receptor to endothelial metabolic gene programs.\",\n      \"evidence\": \"Endothelial-specific Lrp1 KO with metabolic phenotyping, co-IP of LRP1 ICD with PPAR\\u03b3, transcriptional co-activation assays\",\n      \"pmids\": [\"28393867\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of ICD nuclear translocation not defined\", \"Direct DNA target genes not enumerated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Mapped a TLR-driven phosphorylation event (Y4507) that recruits Rab8a/PI3K\\u03b3 to reprogram macrophage inflammatory output, mechanistically defining LRP1 as an anti-inflammatory signaling node.\",\n      \"evidence\": \"CRISPR KO, Y4507 phosphorylation and Rab8a activation assays, recruitment co-IP, cytokine profiling, comparison to Rab8a/PI3K\\u03b3-null phenotypes\",\n      \"pmids\": [\"30208326\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase phosphorylating Y4507 not identified\", \"Relationship to lipid-raft compartmentalization of signaling not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placed LRP1 in a p53-controlled stress circuit, where lethal stress represses LRP1 translation via miR-103/107, establishing a negative feedback loop tied to cell death.\",\n      \"evidence\": \"p53 target identification, miRNA overexpression, transcript/protein measurement under graded stress\",\n      \"pmids\": [\"30089260\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; functional contribution of LRP1 loss to the death decision not isolated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified LRP1 partners controlling proliferation and signaling \\u2014 PARP-1 (endothelial cell cycle), midkine/nucleolin/K-Ras (chondrocyte ERK signaling), and lipid-homeostasis pathways (cPLA2/ABCA1, adipogenesis).\",\n      \"evidence\": \"Co-IP, endothelial KO with retinopathy model, shRNA, downstream signaling and lipid/differentiation assays\",\n      \"pmids\": [\"26634655\", \"31639491\", \"19718435\", \"19823686\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether these intracellular partnerships share a common ICD-dependent mechanism unresolved\", \"Some lipid-homeostasis findings are single-lab Medium evidence\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Clarified that LRP1 endocytic versus signaling activities are spatially segregated into distinct membrane microdomains, with lipid rafts required selectively for Src/ERK signaling.\",\n      \"evidence\": \"Lipid raft fractionation, M\\u03b2CD/fumonisin B1 disruption, kinase activation and neurite/endocytosis assays across neuronal cell types\",\n      \"pmids\": [\"27565578\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular determinants partitioning LRP1 between microdomains not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established neuronal LRP1 as the receptor mediating tau and (later) \\u03b1-synuclein uptake and propagation, identifying lysine residues and N-terminal determinants as the engagement sites \\u2014 a therapeutic target for neurodegenerative spread.\",\n      \"evidence\": \"siRNA/CRISPR KO in H4 cells and iPSC-derived neurons, fluorescent uptake assays, lysine/N-terminus mapping, in vivo AAV tau/\\u03b1-Syn spread models\",\n      \"pmids\": [\"32296178\", \"36056345\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of lysine-dependent binding not solved\", \"Whether the same LRP1 sites bind tau and \\u03b1-Syn unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linked LRP1 genetically to APOE4-driven amyloid-\\u03b2 pathology, showing neuronal LRP1 is required for the APOE4-dependent worsening of A\\u03b2 deposition.\",\n      \"evidence\": \"Neuronal LRP1 conditional KO crossed with APP/PS1 and APOE3/4 replacement mice, plaque quantification, A\\u03b2 ELISA, apoE measurement\",\n      \"pmids\": [\"30741718\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the effect operates via apoE clearance, A\\u03b2 clearance, or both not fully separated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined LRP1's developmental requirement in cardiac neural crest, where a missense (C4232R) variant causes ER retention, reduced surface receptor, and outflow-tract congenital heart defects.\",\n      \"evidence\": \"Knock-in missense and CNC-specific conditional KO mice, outflow morphometry, ER retention, migration and focal-adhesion assays\",\n      \"pmids\": [\"32546759\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise signaling pathway (Wnt and others) downstream of LRP1 in CNCs not fully resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established endothelial LRP1 as a guardian of blood-brain barrier integrity by suppressing the cyclophilin A\\u2013MMP-9 pathway, with two independent rescue strategies confirming causality.\",\n      \"evidence\": \"Endothelial-specific KO, cyclophilin A inhibitor and endothelial LRP1 gene-therapy rescue, BBB, neuron loss and behavior readouts; CNS-endothelial KO replicating tight junction/P-gp loss\",\n      \"pmids\": [\"33533918\", \"34147102\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How LRP1 represses endothelial cyclophilin A mechanistically not fully defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified LRP1 as a direct, broadly used viral entry factor, with bunyavirus glycoproteins binding specific ectodomain clusters and RAP/anti-LRP1 reagents conferring in vivo protection.\",\n      \"evidence\": \"Genome-wide CRISPR and haploid screens, direct glycoprotein-cluster binding (SPR/co-IP), RAP and neutralizing antibody protection in cells and mice for RVFV, OROV, SFTSV and others\",\n      \"pmids\": [\"34559985\", \"35939689\", \"35939689\", \"40301361\", \"37072184\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural details of glycoprotein-cluster recognition vary by virus\", \"Whether endogenous ligands compete with viral glycoproteins not resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Resolved how surface LRP1 abundance is set by dedicated trafficking factors \\u2014 ANKS1A binding NPXY motifs and Rab43 mediating anterograde transport \\u2014 with ANKS1A loss impairing BBB A\\u03b2 clearance.\",\n      \"evidence\": \"Co-IP (ANKS1A-NPXY; Rab43-CD91), endothelial ANKS1A KO and Rab43 KO, surface LRP1/A\\u03b2 clearance and efferocytosis assays, AD and ALI mouse models, gene therapy rescue\",\n      \"pmids\": [\"38123547\", \"35392093\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Rab43-CD91 trafficking validated in single lab\", \"Interplay between ANKS1A and Rab43 in the same transport step not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated organ-specific viral disease driven by LRP1, with hepatocyte LRP1 dictating RVFV hepatic tropism and severity.\",\n      \"evidence\": \"Hepatocyte-specific Lrp1 conditional KO, RVFV liver replication and survival, tissue-specific viral load comparison\",\n      \"pmids\": [\"37450601\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why hepatocyte LRP1 dominates tropism over other tissues not mechanistically explained\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Uncovered new disease-relevant axes \\u2014 astrocytic LRP1 enabling mitochondria transfer via lactate/ARF1 lactylation control, and tumoral LRP1 as a PCSK9 target repressing metastasis-suppressor genes.\",\n      \"evidence\": \"Astrocyte-specific LRP1 manipulation with glycolysis/lactylation/mitochondria-transfer assays and ischemia-reperfusion model with human CSF correlation; PCSK9 gain/loss mouse models with XAF1/USP18 readout and anti-PCSK9 therapy\",\n      \"pmids\": [\"38906140\", \"39657676\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular link between LRP1 and ARF1 lactylation incompletely defined\", \"How PCSK9 engagement of LRP1 represses XAF1/USP18 not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Mapped VWF clearance to a defined LRP1 interaction, with VWF-A1 lysines K1405-K1408 binding LRP1 clusters II and IV, and showed an aptamer can block macrophage-mediated VWF clearance.\",\n      \"evidence\": \"Alanine mutagenesis, ELISA/SPR cluster binding, in vivo VWF clearance, BT200 aptamer competition\",\n      \"pmids\": [\"38996211\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of dual cluster II/IV engagement not solved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined a nuclear LRP1-c-Jun interaction controlling fibroblast CCL2 production and fibroblast-macrophage crosstalk in psoriasis, providing a druggable LRP1 \\u03b2-chain interface.\",\n      \"evidence\": \"Direct celastrol-\\u03b2-chain binding, co-IP of \\u03b2-chain with c-Jun, fibroblast-specific LRP1 KO, murine and primate psoriasis models\",\n      \"pmids\": [\"40177548\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; how the \\u03b2-chain reaches the nucleus to engage c-Jun not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how LRP1's many functions \\u2014 endocytosis, membrane signaling, and nuclear transcriptional partnerships (PPAR\\u03b3, PARP-1, c-Jun) \\u2014 are mechanistically coordinated, including the cleavage/translocation events that generate signaling fragments and the structural rules governing its promiscuous ligand recognition.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unifying structural model for ligand-cluster specificity across diverse cargoes\", \"Pathway from membrane LRP1 to ICD nuclear function not biochemically resolved\", \"Kinases and adaptors coupling LRP1 phosphorylation to specific outputs incompletely defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [0, 1, 3, 14, 18, 26, 31, 38]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [28, 32, 35, 41, 42]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [11, 22, 8, 17]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [21, 45, 19]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [20, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 22, 40, 4]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [4, 27, 34]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [14, 18]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [21, 45]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [9, 33]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 3, 11, 20, 13]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [4, 14, 18, 38]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [22, 17, 11, 8]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [24, 28, 32, 35, 37]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [15, 16, 36, 21]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [12, 17, 27, 44]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [33, 34]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"LEPR\", \"PPARG\", \"PARP1\", \"JUN\", \"SHC1\", \"RAB8A\", \"ANKS1A\", \"RAB43\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win"}}